

Andrew Saxon, M.D.

Professor (rehire)
Professor and Chief Emeritus
Clinical Immunology/Allergy
Department of Medicine
UCLA School of Medicine
52-262 Center for the Health Sciences
Los Angeles, CA 90095-1690
Tel: (310) 206-8050 Fax: (310) 206-8622 (FAX)
Email: asaxon@mednet.ucla.edu

EDUCATION:

- o Graduate, Deerfield Academy, Deerfield, Massachusetts, 1964
Cum Laude Society, 1963, 1964
Bausch and Lomb Science Award, 1964
- o A.B., Anthropology, Dartmouth College, Hanover, New Hampshire, 1968
Phi Beta Kappa, 1968
A.B. Magna Cum Laude
Distinction in Anthropology
Founding Fathers Scholar and Scholarship
- o Archaeology/Anthropology (First Class Honors), University of Otago
Dunedin, New Zealand, 1967
- o B.M.S., Dartmouth Medical School, Hanover, New Hampshire, 1970
Dean's Medal as First in Class
- o M.D., Harvard Medical School, Boston, Massachusetts, 1972
Boylston Society, 1971 - 1972

POSTGRADUATE TRAINING:

- o Intern, Straight Medicine, Harbor General Hospital
Los Angeles, California, 1972 - 1973
Outstanding Medical Intern Award
- o Resident, Internal Medicine, Harbor General Hospital
Los Angeles, California, 1973 - 1975
- o Postdoctoral Scholar in Immunology
Department of Microbiology and Immunology
UCLA School of Medicine
Los Angeles, California, 1975 - 1977

CERTIFICATION AND LICENSING:

- o National Board of Medical Examiners (#126793), June 1973
- o Licentiate (#G24948), State of California, July 1973
- o Diplomate American Board of Internal Medicine (#49823), June 1975
- o Diplomate American Board of Allergy and Immunology (#1967), October 1979
- o Diplomate American Board of Diagnostic Laboratory Immunology (#0134), October 1990

PUBLICATIONS

- o Approximately 180 peer-reviewed research publications

PATENTS

- o "Immunoglobulin Trans-spliced Transcripts and Uses Thereof", US patent No 6.030.830
Issued February, 29, 2000
- o "IgE isoforms and Methods of Use" US patent No. 6,043,345
Issued March 28, 2000
- o "Fusion Molecules and Methods for Treatment of Immune Disease" •US patent 7.265.208, 7.534,440
Issued April 19, 2009.
- o Modified Fusion Molecules for Treatment of Allergic Disease. US application 11/050.113, PCT application 06/03562
- o IgE-directed DNA vaccination •US application 06/788457, •PCT application 07/008028

PROFESSIONAL APPOINTMENTS:

- o Professor of Medicine Emeritus (rehire), Department of Medicine, UCLA School of Medicine, 2006.
- o Professor of Medicine, Department of Medicine, UCLA School of Medicine, 1984 – present.
- o Chief, Division of Clinical Immunology/Allergy, UCLA School of Medicine, 1978 – 2006.
- o Associate, UCLA Molecular Biology Institute, 1985 – present.
- o Member, UCLA Jonsson Comprehensive Cancer Center, 1983 – present.
- o Associate Professor of Medicine, Department of Medicine, UCLA School of Medicine, 1980 – 1984.
- o Acting Chief, Division of Clinical Immunology-Allergy, UCLA School of Medicine, 1977 - 1978
- o Assistant Professor of Medicine, Department of Medicine, UCLA School of Medicine, 1977 - 1980

PROFESSIONAL ACTIVITIES, UCLA:

Division of Clinical Immunology/Allergy Activities:

- o Founder: Division of Clinical Immunology-Allergy, Department of Medicine, UCLA School of Medicine, 1977. The Division now includes 6 full-time faculty members and a broad array of research scientists, technicians, and administrative support persons. I have been funded continuously by the NIH since 1977 and currently have been awarded 3 NIH research grants and 1 NIH training grant.
- o Established the post-doctoral training program in Adult Clinical Immunology and Allergy. This was later combined with the ongoing Pediatric training program so that now I was Co-Director of the Conjoint Adult/Pediatric training program in Allergy and Clinical Immunology for about 25 years. Initiated the UCLA Basic and Clinical Immunology conjoint teaching in 1977 that is now carried out in conjunction with the Department of Pediatrics.

Departmental Activities (selected):

- o Department of Medicine Division Chiefs Committee, 1977 - 2006
- o Department of Medicine Subspecialties Committee, 1999 - 2006
- o Department of Medicine Honors Committee 1984 - 1987
- o Department of Medicine Curriculum Committee 1989 - 1991
- o Department of Medicine Chairman Search Committee 1991 - 1992

School of Medicine and Campus Activities (selected):

- o Executive Board, UCLA Academic Senate, 1983 - 1984
- o Interim Director - UCLA AIDS Center, 1985
- o Associate Director - UCLA AIDS Center, 1986 - 1990
- o Howard Hughes Faculty Search Committee, 1986 - 1991
- o Dean's Bridge Grant Selection Committee 1995- present
- o Co-Director, Center for Interdisciplinary Research in Immunologic Diseases Grant (CIRID) at UCLA, involving investigators from multiple School of Medicine Departments, as well as the School of Nursing, 1988 - to 1993.
- o Director, UCLA Asthma, Allergy and Immunologic Disease Center 1993 – 2006, Co Director 2006 - present. This Center, funded by the National Institutes of Health (National Institute of Allergy and Infectious Disease and the National Institute Environmental Health and Sciences) is dedicated to determining the relationship between environmental factors, the immune system and specific disease processes
- o Principal Investigator: Basic and Clinical Immunology Training Grant, providing for graduate and post-graduate training positions to training preceptors in both the School of Medicine and the College of Letters and Science, 1990 - present
- o Numerous search committees.

PROFESSIONAL ACTIVITIES, OUTSIDE UCLA:

National Scholarly Organization Activities (selected):

- o American Academy of Allergy and Immunology, Basic and Clinical Immunology Section, Vice-Chair 1989 - 1990; Chair 1990 - 1991
- o American Academy of Allergy and Immunology, Committees (active) Research Awards committee - Chair, Nominating committee, Primary Immunodeficiency Disease committee, Clinical and Diagnostic Immunology committee.
- o American Association of Immunologists, Program Committee - Clinical Immunology Section, Co-Chair 1994 - 1996
- o American Association of Immunologists, Program Committee - Immediate Hypersensitivity Section, Co-Chair 1990 - 1991; Chair 1991 - 1993
- o American Federation for Clinical Research, National Counselor, 1981 - 1986
- o American Federation for Clinical Research, Public Policy Committee: 1982 - 1986
- o American Federation for Clinical Research, Publications Committee: 1983 - 1986
- o Clinical Immunology Society, Council Member and Executive Committee, 1992- present
- o Clinical Immunology Society, President, 1999 - 2000
- o Clinical Immunology Society, Publications Committee, 1987 - 1998, Chair, 1995 - 1998
- o Dartmouth Medical School Admissions Support Committee, 1983 - 1988

- o National Institute of Allergy and Infectious Diseases: Co-chair for Allergy & Immediate Hypersensitivity 1996-7; Member 1989 - 1990
Task Force on Asthma and Other Allergic Diseases/New Initiatives in Immunology
- o National Institute of Allergy and Infectious Diseases: Expert Panel on the Extramural Asthma and Allergy Research Program, Co-Chair, 2000
- o Pan-American Group on Immunodeficiency, Co-founder and Member of Executive Council 1995 - present
- o National Institute of Allergy and Infectious Diseases: Expert Panel on Food Allergy Research, Co-Chair, 2003
- o Task Force on Asthma and Other Allergic Diseases/New Initiatives in Immunology NIH, 2002
- o U.S. Judiciary impartial expert witness: Swine Flu Litigation, 1984 - 1988

Research Peer Review Funding Responsibilities (selected):

- o Immune Tolerance Network, Member and Co-Chair, Section on Allergy, Member of National Steering Committee and National Executive Committee, 2000 - present
- o Advisory Council ad hoc member, National Institute of Allergy and Infectious Diseases, 1991
- o Chair of Asthma, Allergy and Immunologic Disease Center Review, National Institute of Allergy and Infectious Diseases, 1994 and 1999.
- o Co-chair of Human Immunology Think Tank, National Institute of Allergy & Infectious Diseases, 2001
- o Reviewer:
 - American Arthritis Foundation
 - Human Frontier Science Program Organization (Europe)
 - Medical Research Council (Australia)
 - Medical Research Council (Canada)
 - Medical Research Council (United Kingdom)
 - National Science Foundation
 - NIH Study Sections: Ad Hoc: Immunobiology, Allergy and Immunology, Immunological Sciences, Experimental Immunology
 - Veterans' Administration: Immunology Merit Review Board

Journal Stewardship:

- o Editor-in-Chief: Clinical Immunology, 1999 - present
- o Founder and Editor-in-Chief: AIDS Medical Update, 1983 - 1992
- o Executive Editor: Clinical Immunology Spectrum, 1991 - 1996
- o Associate Editor-in-Chief: The Immunologist, 1996 - 1999
- o Associate Editor: AIDS Targeted Information Newsletter, 1987 - 1993
- o Associate Editor: Journal of Immunology, 1982 - 1987
- o Founder and Consulting Editor: AIDS Nursing Update, 1987 - 1992
- o Associate Editor-in-Chief: Clinical Immunology & Immunopathology - 1998
- o Editorial Board: Committee on Publishing Ethics
 - Journal Allergy and Clinical Immunology, 1981 - 1986
 - Journal of Clinical Immunology, 1982 - 1989
 - Clinical Research, 1984 - 1986
 - Disease Markers, 1985 - present
- o Member, Committee on Publishing Ethics, Elsevier 2008-present

TRAINING/TEACHING ACTIVITIES (selected):

- o Co-Director: Combined Fellowship in Pediatric and Adult Immunology and Allergy, 1979 - 2003
- o Director: Fellowship Program in Adult Clinical Immunology/Allergy (CIA), UCLA School of Medicine, 1977 - 1979
- o American Academy of Allergy/Immunology: Trainee Award Committee Member, 1989 - 1991
- o Member: Training Directors Committee, American Academy of Allergy and Immunology, 1980 - 2000
- o Member: Training Directors Committee, American College of Allergy and Immunology, 1989 - 2000
- o Chairman: UCLA Department of Medicine Honors Preceptor Program, 1984 - 1987
- o Organizer and/or Instructor: various courses in Medicine and Microbiology & Immunology, as well as in continuing medical education, 1977 - present

PUBLIC SERVICE:

- o Asthma and Allergy Foundation of America (Los Angeles Chapter): Board of Directors, 1981 - 1985
- o Asthma and Allergy Foundation of America (Los Angeles Chapter): Medical Advisory Board, 1986 - 1999; Chairman, 1990 - 1999
- o FDA Advisory Panel member - Allergenic products 1997 - 2002
- o Immune Deficiency Foundation of America: Medical Advisory Board, 1990 - 2004
- o PADI Foundation: Board of Directors, 1991- present, Secretary and Chief Financial Officer 1992 - present.
- o Chair, USC Children's Center Advisory Committee 1999-present
- o Chair, Food Allergy Initiative Medical Advisory Board 2001 - 2006

PROFESSIONAL SOCIETIES:

- o Association of American Physicians
- o American Society for Clinical Investigation
- o American Federation for Clinical Research
- o American Association of Immunologists
- o American Academy of Allergy and Clinical Immunology
- o American College of Allergy and Immunology
- o Clinical Immunology Society
- o Collegium Internationale Allergologicum
- o Los Angeles Society of Allergy and Clinical Immunology
- o Pan-American Group on Immunodeficiency
- o Society of Toxicology, Immunotoxicology Section
- o Western Association of Physicians

HONORS: (selected)

- Recipient: Allergic Diseases Academic Award: National Institute of Allergy and Infectious Diseases, 1978 – 1983.
- University Visiting Professorship: Singapore Post Graduate School of Medicine and Singapore General Hospital, Singapore, 1985.
- Swineford Memorial Lectureship: University of Virginia, Charlottesville, VA, 1987.
- Catholic University Visiting Lectureship in Immunology: Catholic University, Santiago, Chile, 1987
- Rabiner Visiting Professor: University of Oregon School of Medicine, Good Samaritan Hospital, Portland, OR, 1988.
- UCLA Visiting Professorship: Harbor General Hospital/UCLA, Torrance, CA, 1988.
- Robert Orange Memorial Lectureship, University of Toronto, Hospital for Sick Children, Toronto, Canada, 1988.
- Visiting Professor, National Jewish Center for Immunology, Denver, CO, 1990.
- American College of Allergy & Immunology Visiting Professor, University of Oklahoma, Tulsa, OK, 1991.
- American College of Allergy & Immunology Visiting Professor, Temple University, Philadelphia, PA., 1992.
- Goodman Family Visiting Professor, Santa Monica Hospital Medical Center, Los Angeles, CA 1994
- UCLA Medical Sciences Research Award Recipient, 1994.
- University of Illinois College of Medicine Visiting Professor 1995.
- Keynote speaker First Japanese Clinical Immunology and Allergy Society meeting and International Guest of Honor, Japanese Society of Immunology, Allergy and Otolaryngology, 1996.
- Arbesman Commemorative Lecturer - American Academy of Allergy, Asthma and Immunology, 1997.
- National Institute of Allergy and Infectious Diseases 50th Anniversary Symposium Speaker, ATS, 1999.
- Recipient, Stein Oppenheimer Award 1999.
- William Pierson Lectureship, American Academy of Allergy, Asthma and Immunology, Scripps Mercy Hospital, 2000.
- First Annual Feng Pao Hsui Lectureship, Singapore Society of Immunology, Rheumatology & Allergy Society, 2000.
- Keynote Speaker, Keystone Symposium on Asthma, Santa Fe, New Mexico, Feb. 2002
- Distinguished Visiting Professor in Immunology, Biology of Inflammation Center at Baylor College of Medicine, Feb. 2004.
- Presidential Award, Clinical Immunology Society, 2005.
- Physician-of-the-Year honoree, Asthma and Allergy Foundation of America, Los Angeles Chapter, 2005.
- Carolyn and Warren Richards Allergy Lectureship, Children's Hospital of Los Angeles, Keck School of Medicine, University of Southern California, 2006.
- Distinguished Service Award, Clinical Immunology Society, 2008

PUBLICATIONS

Research Papers - peer reviewed

1. Saxon, A. and Higham, C.W.F. Identification and interpretation of growth rings in the secondary dental cementum of *Ovis aris* L. *Nature*. 219:634. 1968.
2. Saxon, A. and Higham, C.W.F. A new research method for economic prehistorians. *American Antiquity*. 34:303. 1969.
3. Ferm, V.H. and Saxon, A. Amniotic fluid volumes in experimentally induced renal agenesis and anencephaly. *Experimentia*. 27:1066. 1971.
4. Ferm, V.H., Saxon, A. and Smith, B.M. The teratogenic profile of sodium arsenate in the golden hamster. *Arch Environ Health*. 22:557. 1971.
5. Hoefnagel, D., Pomeroy, J., Wurster, D. and Saxon, A. Congenital athetosis, mental deficiency, dwarfism and laxity of skin and ligaments. *Helv Paediat Acta*. 26:397. 1971.
6. Saxon, A., Busch, G.J., Merrill, J.P. and Wilson, R. Renal transplantation in primary hyperoxaluria. *Arch of Internal Med*. 133:464. 1974.
7. Saxon, A. and Kattlove, H.E. Platelet inhibition by sodium nitroprusside, a smooth muscle inhibitor. *Blood*. 46:957. 1976.
8. Saxon, A., Feldhaus, J., and Robins, R.A. Single step separation of human T and B cells using AET treated SRBC rosettes. *J Immunol Methods*. 12:285. 1976.
9. Cline, M.J., Opelz, G., Saxon, A., Fahey, J.L. and Golde, D.W. Autoimmune panleukopenia. *N Engl J Med*. 295:1489. 1976.
10. O'Toole, C., Saxon, A. and Bohrer, R. Human lymph node lymphocytes fail to effect lysis of antibody coated target cells. *Clin Exp Immunol*. 27:165. 1977.
11. Bonavida, B., Robins, R.A. and Saxon, A. Lectin-dependent cellular cytotoxicity in man. *Transplantation*. 23:261. 1977.
12. Golde, D.W., Saxon, A. and Stevens, R.H. Macroglobulinemia and hairy-cell leukemia. *N Engl J Med*. 296:92. 1976.
13. Golde, D.W., Stevens, R.H., Quan, S.G. and Saxon, A. Immunoglobulin synthesis in hairy cell leukemia. *Brit Journal Haematology*. 35:359. 1977.
14. Saxon, A. and Portis, J. Lymphoid subpopulation changes in regional lymph nodes in squamous head and neck cancer. *Cancer Res*. 37:1154. 1977.
15. Saxon, A. and Portaro, J. Preservation of *in vitro* biologic functions in regional lymph node lymphocytes in squamous head and neck cancer. *Cancer Res*. 37:1159. 1977.
16. Saxon, A., Morledge, D. and Bonavida, G. Histamine receptor leukocytes (HRL): Organ and lymphoid subpopulation distributions in man. *Clin Exp Immunol*. 28:394. 1977.
17. Saxon, A., Stevens, R.H., Ashman, R.A. and Parker, N. Dual immune defects in non-granulomatous ulcerative jejunoileitis with hypogammaglobulinemia. *Clin Immunol Immunopath*. 8:272. 1977.
18. Saxon, A., Stevens, R.H. and Ashman, R.A. Regulation of immunoglobulin production in human peripheral blood leukocytes: Cellular interactions. *J. Immunol*. 118:1872. 1977.
19. Pratt, H.P.M., Fitzgerald, P.A. and Saxon, A. Synthesis of sterol and phospholipid induced by the interaction of phytohemagglutinin and other mitogens with human lymphocytes and their relation to blastogenesis and DNA synthesis. *Cell Immunol*. 32:160. 1977.
20. Saxon, A., Stevens, R.H., Raimer, S.J., Clements, P.J. and Yu, D.T.Y. Glucocorticoids administered *in vivo* inhibit human suppressor T lymphocyte function and diminish B lymphocyte responsiveness in *in vitro* immunoglobulin synthesis. *J Clin Invest*. 61:922. 1978.

21. Saxon, A., Stevens, R.H., Quan, S.G. and Golde, D.W. Immunologic characterization of hairy cell leukemias in continuous culture. *J Immunol.* 120:777, 1978.
22. Fiala, M., Chatterjee, S.N., Carson, S., Poolsawat, S., Heiner, D.C., Saxon, A. and Guze, L.B. Cytomegalovirus retinitis secondary to chronic viremia in phagocytic leukocytes. *Amer J Ophthalmol.* 84:567, 1977.
23. Fiala, M., Chatterjee, S., Ellis, R., Imparato, B., Bahna, S. and Saxon, A. Fever of undetermined origin: Role of cytomegalovirus and Epstein-Barr virus. *West J Med.* 129:263-266, 1978.
24. Pratt, H.P.M., Saxon, A. and Graham, M.L. Membrane lipid changes associated with malignant transformation and normal maturation of human lymphocytes. *Leukemia Research.* 2:1, 1978.
25. Saxon, A. and Stevens, R.H. Suppression of immunoglobulin production in normal human blood characterization of the cells responsible and mediation by a soluble T lymphocyte derived factor. *Clin Immunol Immunopath.* 10:427, 1978.
26. Stevens, R.H. and Saxon, A. Anti-human helper T-lymphocyte antiserum: Generation and functional characterization. *Clin Immunol Immunopath.* 10:438, 1978.
27. Saxon, A., Stevens, R.H. and Golde, D.W. T-lymphocyte variant of hairy cell leukemia. *Ann Int Med.* 88:323, 1978.
28. Stevens, R.H. and Saxon, A. Immunoregulation in humans: Control of anti-tetanus toxoid antibody production after booster immunization. *J Clin Invest.* 62:1154, 1978.
29. Stevens, R.H., Thiele, C. and Saxon, A. The production of a soluble human T lymphocyte derived factor which substitutes for helper T lymphocytes in the *in vitro* production of immunoglobulin. *Immunology.* 36:407, 1979.
30. Saxon, A. and Stevens, R.H. Human T lymphocyte-derived helper factor (HHF): Cellular and physical characterization. *Clin Immunol Immunopath.* 12:82, 1979.
31. Fitch, J.H., Cline, M.J., Saxon, A. and Golde, D.W. Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus: Recovery after exchange plasmaphoresis. *Amer J of Med.* 66:537, 1979.
32. Saxon, A., Stevens, R.H. and Golde, D.W. Helper and suppressor T-lymphocyte leukemia in Ataxia Telangiectasia. *N Engl J Med.* 300:700, 1979.
33. Stevens, R.H. and Saxon, A. Reduced *in vitro* production of anti-tetanus toxoid antibody after repeated *in vivo* immunization with tetanus toxoid. *J Immunol.* 122:592, 1979.
34. Stevens, R.H. and Saxon, A. Differential synthesis of IgM and IgG antitetanus toxoid antibody *in vitro* following *in vivo* booster immunization of humans. *Cell Immunol.* 45:142, 1979.
35. Stevens, R.H., Macy, E., Morrow, C. and Saxon, A. Characterization of a circulating subpopulation of spontaneous anti-tetanus toxoid antibody producing B cells following *in vivo* booster immunization. *J Immunol.* 122:2498, 1979.
36. Bluming, A., Cohen, H. and Saxon, A. Angioimmunoblastic lymphadenopathy with dysproteinemia: A pathogenetic link between physiologic lymphoid proliferation and malignant lymphoma. *Amer J Med.* 67:421, 1979.
37. Krantman, H.J., Stiehm, E.R., Stevens, R.H., Saxon, A. and Seeger, R.C. Abnormal B cell differentiation and variable increased T cell suppression in immunodeficiency with hyper-IgM. *Clin Exp Immunol.* 40:147, 1980.
38. Ashman, R.F., Saxon, A. and Stevens, R.H. Profile of multiple lymphocyte functional defects in acquired hypogammaglobulinemia derived from *in vitro* cell recombination analysis. *J Allergy Clin Immunol.* 65:242, 1980.
39. Saxon, A. and Stevens, R.H. Stimulation and regulation of human IgE production *in vitro* using peripheral blood lymphocytes. *Clin Immunol Immunopath.* 14:474, 1979.
40. Saxon, A., Kobayashi, R.H., Stevens, R.H., Stiehm, E.R. and Siegel, S.C. *In vitro* analysis of humoral immunity with normal immunoglobulins in antibody deficiency. *Clin Immunol Immunopath.* 17:235, 1980.

41. Stevens, R.H., Tamaroff, M. and Saxon, A. Inability of patients with common variable hypogammaglobulinemia to generate lymphoblastoid B cells following booster immunization. *Clin Immunol Immunopath.* 16:336. 1980.
42. Saxon, A., Morrow, C. and Stevens, R.H. Subpopulations of circulating B cells and regulatory T cells involved in *in vitro* immunoglobulin E production in atopic patients with elevated serum immunoglobulin E. *J Clin Invest.* 65:1457. 1980.
43. Saxon, A., Tamaroff, M.A., Morrow, C. and Stevens, R.H. Impaired generation of spontaneous and mitogen-reactive anti-tetanus toxoid antibody producing B cells following repetitive *in vivo* booster immunization. *Cell Immunol.* 59:82. 1981.
44. Boxer, R.J., Sofen, H. and Saxon, A. The detection of transitional cell bladder cancer antigens on established cell lines. *Invest Urology.* 19:70. 1981.
45. Saxon, A., Kaplan, M. and Stevens, R.H. Isotype specific human B lymphocytes that produce immunoglobulin E *in vitro* when stimulated by pokeweed mitogen. *J Allergy Clin Immunol.* 66:231. 1980.
46. Stevens, R.H. and Saxon, A. Antigen-induced suppression of human *in vitro* pokeweed mitogen stimulated antibody production. *Cell Immunol.* 55:85. 1980.
47. Foon, K.A., Naiem, F., Saxon, A., Stevens, R.H. and Gale, R.P. Leukemia of T-helper lymphocytes: Clinical and functional features. *Leukemia Research.* 5:1. 1981.
48. Saxon, A., Thiele, C.J., Moroz, C. and Stevens, R.H. Adenosine receptor lymphocytes in humoral immunodeficiency. *J Clin Immunol.* 1:131. 1981.
49. Krantman, H.J., Saxon, A., Stevens, R.H. and Stiehm, E.R. Phenotypic heterogeneity in X-linked infantile agammaglobulinemia with *in vitro* monocyte suppression of immunoglobulin synthesis. *Clin Immunol Immunopath.* 20:170. 1981.
50. Church, J.A., Isacacs, H., Saxon, A., Keens, T.G. and Richards, W. Lymphoid interstitial pneumonitis and hypogammaglobulinemia in children. *Amer Rev Resp Dis.* 124:491. 1981.
51. Cannon, R.A., Blum, P.M., Ament, M.E., Byrne, W.J., Soderberg-Warner, M., Seeger, R.C., Saxon, A. and Stiehm, E.R. Reversal of enterocolitis-associated combined immunodeficiency by plasma therapy. *J Pediatrics.* 101:711. 1982.
52. Saxon, A., McIntyre, R.E., Stevens, R.H. and Gale, R.P. Lymphocyte dysfunction in chronic graft versus host disease. *Blood.* 58:746. 1981.
53. Ahmed, R.A., Sofen, H. and Saxon, A. Detection of an antisquamous antibody in multiple kartoacanthoma. *Clin Immunol Immunopath.* 22:20. 1982.
54. Gottlieb, M.S., Schroff, R., Schanker, H.M., Weisman, J.D., Fan, P.T., Wolf, R.A. and Saxon, A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. *N Engl J Med.* 305:1425. 1981.
55. Barbers, R.G., Shih, W.W.H. and Saxon, A. *In vitro* depression of human lymphocyte mitogen response (phytohemagglutinin) by asbestos fibres. *Clin Exp Immunol.* 48:602. 1982.
56. Schwartz, A.G., Targan, S.R., Saxon, A. and Weinstein, W.M. Sulfasalazine-induced exacerbation of ulcerative colitis. *N Engl J Med.* 306:409. 1982.
57. Ahmed, A.R., Stevens, R.H. and Saxon, A. Production of antibasement membrane zone antibody by peripheral blood leukocytes bullous pemphigoid patients. *J Clin Immunol.* 2:179. 1982.
58. Thompson, L.F., Saxon, A., O'Connor, R.D. and Fox, R.I. Ecto-5'-nucleotidase activity in human T cell subsets: Decreased numbers of ecto-5'-nucleotidase positive cells from both OKT4+ and OKT8+ cells in patients with hypogammaglobulinemia. *J Clin Invest.* 71:892. 1983.
59. Rohr, A., Hassner, A. and Saxon, A. Rhinopharyngoscopy for the evaluation of allergic-immunologic disorders. *Ann Allergy.* 50:380. 1983.
60. Ahmed, R.A., Murahata, R.I., Schroff, R.W., Stevens, R.H. and Saxon, A. Production of pemphigus antibody *in vitro* and analysis of T cell subsets. *J Clin Immunol.* 3:241. 1983.

61. Hassner, A. and **Saxon, A.** Inhibition of ongoing myeloma IgE synthesis *in vitro* by activated human T cells. *J Immunol.* 130:1567. 1983.
62. Schanker, H.M., Young, R., Cahan, L., Schroff, R. and **Saxon, A.** Effect of midbrain stimulus induced analgesia on immune function in humans. *J Neuroimmunol.* 5:185. 1983.
63. Denis, K.A., Wall, R. and **Saxon, A.** Human-human B cell hybridomas from *in vitro* stimulated lymphocytes patients with common variable immunodeficiency. *J Immunol.* 131:2273. 1983.
64. Hassner, A. and **Saxon, A.** Isotype-specific human suppressor T cells for IgE synthesis activated by IgE-Anti-IgE immune complexes. *J Immunol.* 132:2844. 1984.
65. Kodo, H., Gale, P. and **Saxon, A.** Antibody synthesis by bone marrow cells *in vitro* following primary and booster tetanus toxoid immunization in humans. *J Clin Invest.* 73:1377. 1984.
66. Rohr, A.S., Marshall, N.A. and **Saxon, A.** Successful immunotherapy for *Triatoma protracta*-induced anaphylaxis. *J All. Clin Immunol.* 73:369. 1984.
67. **Saxon, A.**, Hassner, A., Swabb, E.A., Wheeler, B. and Adkinson, N.F. Lack of cross-reactivity between Aztreonam, a monobactam antibiotic, and Penicillin in penicillin allergic subjects. *J Inf Dis.* 149:16. 1984.
68. **Saxon, A.** and Barnett, E. Human auto-anti-idiotypes regulating T cell mediated reactivity to tetanus toxoid. *J Clin Invest.* 73:342. 1984.
69. Ochs, H.D., Allred, R.U., Ammann, A.J., Budinger, M.D., Cowan, M.T., Fischer, S.H., Rousell, R.H., **Saxon, A.**, Wara, D. and Wedgewood, R. Comparison of high dose, low dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. *Amer J Med.* 76:78. 1984.
70. Kanowitz-Klein, S. and **Saxon, A.** Fc epsilon receptors on human cell lines and peripheral blood lymphocytes detected by binding of IgE immune complexes. *J Clin Immunol.* 5:38. 1985.
71. **Saxon, A.**, Swabb, E. and Adkinson Jr., N.F. Investigation into the immunologic cross-reactivity of Aztreonam with other beta-lactam antibodies. *Amer J Med.* 78:19. 1985.
72. Schanker, H.M., Rajfer, J. and **Saxon, A.** Recurrent respiratory disease, azoospermia and nasal polyposis: A syndrome that mimics cystic fibrosis and immotile cilia syndrome. *Arch Int Med.* 145:2201. 1985.
73. Marshall, N., Liebhaber, M., Dyer, A. and **Saxon, A.** The prevalence of allergic sensitization to *Triatoma protracta* (Heteroptera: Reduviidae) in a Southern California U.S.A. Community. *J Med Entomol.* 23:117. 1986.
74. Kanowitz-Klein, S. and **Saxon, A.** Regulation of ongoing IgE synthesis by human T cell supernatants derived from atopic and nonatopic donors. *Int Arch Allergy Appl Immunol.* 80:33. 1986.
75. Ashida, E.R. and **Saxon, A.** Home intravenous immunoglobulin therapy by self-administration. *J Clin Immunol.* 6:306. 1986.
76. Marshall, M.S., Chapman, M.D. and **Saxon, A.** Species specific allergens from the salivary glands of *Triatominae* (Heteroptera: Reduviidae). *J Allergy Clin Immunol.* 78:430. 1986.
77. Chapman, M.D., Marshall, N.A. and **Saxon, A.** Identification and partial purification of species specific allergens from *Triatoma protracta* (Heteroptera: Reduviidae). *J Allergy Clin Immunol.* 78:436. 1986.
78. **Saxon, A.**, Mitsuyasu, R., Stevens, R., Champlin, R.E., Kimata, H. and Gale, R.P. Designed transfer of specific immune responses with bone marrow transplantation. *J Clin Invest.* 78:959. 1986.
79. **Saxon, A.**, Tsui, F. and Martinez, O. Jacalin, an IgA binding lectin, inhibits differentiation of human B cells by both a direct effect and by activating T suppressor cells. *Cell Immunol.* 104:134. 1987.
80. **Saxon, A.** and Weinstein, R. Oral administration of bovine colostrum anti-cryptosporidia antibody fails to alter the course of human cryptosporidiosis. *J Parasitology* 73:413-415. 1987.

81. Sherr, E.H., Stein, L.D., Dosch, H.M. and Saxon, A. IgE enhancing activity directly and selectively affects activated B cells: Evidence for a human IgE differentiation factor. *J Immunol.* 138:3836. 1987.
82. Kanowitz-Klein, S., Saxon, A., Uittenbogaart, C.H. Constitutive production of B cell differentiation factor-like activity by human T and B cell lines. *Euro. J. Immunol.* 17:593-598. 1987.
83. Kimata, H., Shanahan, F., Brogan, M., Targan, S. and Saxon, A. Modulation of ongoing human immunoglobulin synthesis by natural killer cells. *Cell Immunol.* 107:74. 1987.
84. Sherr, E.H., Saxon, A., Wells, J.R. Functional and phenotypic characterization of human B lymphocyte subsets isolated by unit gravity sedimentation. *Int Arch Allergy Appl Immunol.* 85:154. 1988.
85. Clement, L.T., Plaeger-Marshall, S., Hass, A., Saxon, A. and Martin, A.M. Bare lymphocyte syndrome: Consequences of absent class II major histocompatibility antigen expression for B lymphocyte differentiation and function. *J Clin Invest.* 81:669. 1988.
86. Saxon, A., Adelman, D. C., Patel, A., Hajdu, R. and Calandra, G.B. Imipenem cross-reactivity with penicillin in humans. *J Allergy Clin Immunol.* 82:213. 1988.
87. Sherr, E.H., Adelman, D.C., Saxon, A., Gilly, M., Wall, R. and Sidell, N. Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency. *J Exp Med.* 168:55. 1988.
88. Kimata, H. and Saxon, A. A subset of natural killer cells is induced by immune complexes to display Fc receptors for IgE and IgA and demonstrate isotype regulatory function. *J Clin Invest.* 82:160. 1988.
89. Kanowitz-Klein, S., Hofman, F. and Saxon, A. Expression of Fc ϵ receptors and surface and cytoplasmic IgE on human fetal and adult lymphopoietic tissue. *Clin Immunol Immunopath.* 48:214. 1988.
90. Kimata, H., Sherr, E. and Saxon, A. Human natural killer cells produce a late acting B cell differentiation activity. *J. Clin. Immunol.* 8:381. 1988.
91. Macy, E., Kemeny, M. and Saxon, A. Enhanced ELISA: How to measure less than 10 picograms of a specific protein (immunoglobulin) in less than 8 hours. *FASEB Journal.* 2:3003. 1988.
92. Sherr, E., Macy, E., Kimata, H., Gilly, M. and Saxon, A. Binding the low affinity Fc ϵ R on B cells suppresses ongoing human IgE synthesis. *J. Immunol.* 142:481. 1989.
93. Ch'ng, H.H., Shaw, D., Klesius, P. and Saxon, A. Inability of oral bovine transfer factor failed to eradicate cryptosporidial infection in a patient with congenital dysgammaglobulinemia. *Clin Immunol Immunopath.* 50:402. 1989.
94. Saxon, A., Giorgi, J.V., Sherr, E.H. and Kagan, J.M. Failure of B cells in common variable immunodeficiency to transit from proliferation to differentiation is associated with altered B cell surface molecule display. *J Allergy Clin Immunol.* 84:44. 1989.
95. Macy, E., Bulpitt, K., Champlin, R.E. and Saxon, A. Anaphylaxis to infusion of autologous bone marrow: An apparent IgE reaction to self, mediated by IgE antibody to bovine serum albumin. *J. Allergy Clin Immunol.* 83:871. 1989.
96. Kagan, J., Champlin R.E. and Saxon A. B-cell dysfunction following human bone marrow transplantation: Functional-phenotypic dissociation in the early post transplant period. *Blood.* 74:777. 1989.
97. Ch'ng, H.H., Ganz, T. and Saxon, A. The utility of detecting autoantibodies against neutrophil cytoplasmic components in Wegener's granulomatosis. *Ann Allergy.* 63:411. 1989.
98. Kimata, H., Berenson, J., Kagan, J. and Saxon, A. Functional human T cell-B cell hybridomas established from fusion of normal T cells and an EBV transformed B cell line. *Clin Immunol Immunopath.* 54:134. 1990.

99. **Saxon, A.**, Shanahan, F., Landers, C., Ganz, T. and Targan, S. A distinct subset of anti neutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. *J Allergy Clin Immunol.* 86:202. 1990.
100. Brieva, J.A., Martin, R.A., Martinez-Maza, O., Kagan, J.M., Merrill, J., **Saxon, A.**, Van Damme, J. and Stevens, R.H. Interleukin 6 is essential for antibody secretion by human *in vivo* antigen-induced lymphoblastoid B cells. *Cellular Immunology* 130:303. 1990.
101. **Saxon, A.**, Ke, Z., Bahtee, L. and Stevens, R.H. Soluble CD23 containing B cell supernatants induce IgE from peripheral blood B lymphocytes and co-stimulates with IL-4 in induction of IgE. *J Allergy Clin Immunol.* 86:333. 1990.
102. Adelman, D.C., Matsuda, T., Hirano, T., Kishimoto, T. and **Saxon, A.** Elevated serum interleukin-6 associated with a failure in B cell differentiation in common variable immunodeficiency. *J Allergy Clin Immunol.* 86:512. 1990.
103. **Saxon, A.**, Macy, E., Witte, O., Tary-Lehmann, M., Denis, K. and Braun, J. Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans. *J. Clin Invest.* 87: 658. 1991.
104. Zhang, Ke, Z., Clark, E.A., and **Saxon, A.** CD40 stimulation provides an interferon- γ independent IL-4 dependent IgE specific differentiation signal directly for human blood and tonsil B cells. *J. Immunol.*, 146:1836-1842. 1991.
105. Sidell, N., Taga, T., Hirano, T., Kishimoto, T., and **Saxon, A.** Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. *J. Immunol.* 146:3809-3814. 1991.
106. Braun, J., Galbraith, L., Valles-Ayoub, V., and **Saxon, A.** Human humoral immunodeficiency results from germinal center B cell arrest. *Immun. Lett.*, 27:205-208. 1991.
107. Adelman, D.C., Yen, T.Y., Cumberland, W.G., Sidell, N. and **Saxon, A.** 13-Cis retinoic acid enhances *in vivo* B-lymphocyte differentiation in patients with common variable immunodeficiency. *J All. Clin Immunol.* 88:705-712. 1991.
108. **Saxon, A.**, Behle, K., Kurbe-Leamer, M., E. E. Max and Ke, Z. Inhibition of human IgE production via Fc ϵ R-II stimulation results from a decrease in the mRNA for secreted but not membrane epsilon (ϵ) heavy chains. *J. Immunol.*, 147:4000-4006. 1991.
109. Tary-Lehmann, M. and **Saxon, A.** Human Mature T Cells which are Anergic *in vivo* Prevail in SCID Mice Reconstituted with Human Peripheral Blood (hu-PBL-SCID mice) *J. Exp. Med.* 175: 503-512. 1992.
110. Sogn, D., Evans, R., Shepard, G.M., Casale, T.B., Condemi, J.J., Greenberger, P.A., Kohler, P.F., **Saxon, A.**, Summers, R.J., VanArsdel Jr, P.P., Massicot, J.G., Blackwelder, W.C. and Levine, B.B. Results of the NIAID collaborative clinical trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. *Arch. Int. Med.* 152:1025. 1992.
111. Zhang, K., **Saxon, A.**, Max, E.E. Two unusual forms of human IgE encoded by alternative RNA splicing of ϵ heavy chain membrane exons. *J. Exp. Med.* 176:233-243. 1992.
112. Storek, J., Schmid, I., Ferrara, S., **Saxon, A.** A novel B-cell stimulation-proliferation assay using simultaneous flow cytometric detection of cell surface markers and DNA content. *J. Immunol. Method.* 151:261-267. 1992.
113. **Saxon, A.**, Sidell, N., Zhang, K. B-cells from subjects with CVI can be driven to Ig production in response to CD40 stimulation. *Cell. Immunol.*, 144:169-181. 1992.
114. Storek, J., Ferrara, S., Rodriguez, C., and **Saxon, A.** Recovery of mononuclear cell subsets after bone marrow transplantation: Overabundance of CD4 $^{+}$ CD8 $^{+}$ dual-positive T cells reminiscent of ontogeny. *J. Hematother.* 1: 303-316. 1992.

115. Geha, R., Buckley, C.E., Greengberger, P., Patterson, R., Polmer, S., **Saxon, A.**, Rohr, A., Yang, W., and Drouin, M. Aspartame is no more likely than placebo to cause urticaria/angioedema: Results of a multicenter, randomized, double-blind, placebo-controlled, crossover study. *J. All. Clin. Immunol.* 92:513-520. 1993.
116. **Saxon, A.**, Keld, B., Braun, J., Dotson, A., and Sidell, N. Long Term Administration of 13-cis Retinoic Acid in Common Variable Immunodeficiency: Circulating IL-6 levels, B cell surface molecule display, and *in vitro* and *in vivo* B cell antibody production. *Immunology*. 80:477-487. 1993.
117. Storek, J., Ferrara, S., Ku, N., Giorgi, J., Champlin, R.E., and **Saxon, A.** Reconstitution of B-cell immunity following bone marrow transplantation: Recapitulation of Ontogeny? *Bone Marrow Transplantation*. 12:387-398. 1993.
118. Zhang, K., Max, E.E., Cheah, H-K., and **Saxon, A.** Complex alternative RNA splicing of ϵ immunoglobulin transcripts produces mRNAs encoding four potential secreted protein isoforms. *J. Biol. Chem.* 269: 456-462. 1994.
119. Uittenbogaart, C.H., Anisman, D.J., Tary-Lehmann, M., Vollger, L.W., Breit, T.M., Van Dongen, J.J.M., and **Saxon, A.** The SCID mouse environment causes immunophenotypic changes of human immature T cell lines. *Int. J. Cancer*. 56: 546-551. 1994.
120. Zhang, K., Mills, F.C., **Saxon, A.** Switch Circles from IL-4 Directed ϵ Class Switching from Human B Lymphocytes: Evidence for Direct, Sequential and Multiple Step Sequential Switch from Mu to Epsilon Immunoglobulin Heavy Chain Gene. *J. Immunol.*, 152: 3427-3435, 1994.
121. Diaz-Sanchez, D., Chegini, S., Zhang, K., **Saxon, A.** CD58 (LFA-3) Stimulation Provides a Signal for Human Isotype switching and IgE Production Distinct from CD40. *J. Immunol.* 153:10-20. 1994.
122. Diaz-Sanchez, D., Dotson, A.R., Takenaka, H., **Saxon, A.** Diesel exhaust particles induce local IgE production *in vivo* in humans and alter the pattern of IgE mRNA isoforms. *J. Clin. Invest.* 94:1417-25. 1994.
123. Tary-Lehmann, M., Lehmann, P.V., Schols, D., Grazia-Roncarolo, M., **Saxon, A.** Anti-SCID mouse reactivity shapes the human CD4⁺ repertoire in hu-PBL-SCID chimeras. *J. Exp. Med.* 180:1817-1827. 1994.
124. Storek, J., King, L., Ferrara, S., Marcello, D., **Saxon, A.**, Braun, J. Abundance of a restricted fetal B cell repertoire in marrow transplant recipients. *Bone Marrow Trans.*, 14: 783-790. 1994.
125. Storek, J., Ferrara, S., Hultin, L.E., Ku, N., Giorgi, J.V., Champlin, R.E., and **Saxon, A.** B cell dysfunction after bone marrow transplantation is associated with decreased Ca⁺⁺ flux upon membrane Ig crosslinking. *Clin. Immunol Immunopath.* 72:210-6. 1995.
126. Takenaka, H., Zhang, K., Diaz-Sanchez, D., Tsien, A., **Saxon, A.** Enhanced human IgE results from exposure to the aromatic hydrocarbons in diesel exhaust: direct effects on B cell IgE production. *J. All. Clin. Immunol.* 95:103-115. 1995.
127. Zhang, K., Cheah, H-K., **Saxon, A.** Secondary deletional recombination of rearranged switch region in Ig isotype switched B cells: A mechanism for isotype stabilization. *J. Immunol.* 154: 2237-2247. 1995.
128. Zhang, K., Diaz-Sanchez, D., **Saxon, A.** Germ-line human epsilon heavy chain gene RNA transcripts utilize the full range of alternative 3' splicing seen in productive epsilon mRNAs. *Immunology*. 85: 228-235. 1995.
129. Xu F., **Saxon, A.** Nguyen, A., Zhang, K., Diaz-Sanchez, D., Nel, A. IL-4 activates a Stat protein which interacts with a GAS-like sequence upstream of the IgE exon in a human B-cell line: Evidence for the involvement of JAK3 kinase and IL-4-Stat., *J. Clin. Invest.*, 96:907-914. 1995.
130. Diaz-Sanchez, D., Zhang, K., Nutman, T.B., **Saxon, A.** Differential regulation of alternative 3' splicing of human epsilon mRNA variants. *J. Immunol.* 155: 1930-1941. 1995.

131. Tary-Lehmann, M., **Saxon, A.**, Lehmann, P.V. The human immune system in hu-pb1-SCID mice. *Immunology Today*. 16:529-33 1995.
132. **Saxon, A.** Keld, B., Diaz-Sanchez, D., Guo, B-C., Sidell, N. B cells from a distinct subset of patients with common variable immunodeficiency have increased CD95 (Apo-1/fas) and diminished CD38 expression and undergo enhanced apoptosis: rescue by CD40 and IL-4. *Clin Exp. Immunol.*, 102: 17-25, 1995.
133. Fujieda, S., Zhang, K., **Saxon, A.** IL-4 plus CD40 mAb Induces Human B Cell Gamma Subclass Specific Isotype Switch: Switching to g1, g3 and g4 but not g2. *J. Immunol.*, 155: 2318-2328, 1995.
134. Guo, B. C. and **Saxon, A.** B Cell Lines from a Subset of Patients with Common Variable Immunodeficiency Undergo Enhanced Apoptosis Associated with Increased CD95 (Apo-1/fas) Display, Diminished CD38 Expression, and Decreased IgG and IgA Production. *Cell Immunology*. 166:83-92, 1995.
135. Lyczak, J., Zhang, K., **Saxon, A.**, Morrison, S., Expression of Novel Secreted Isoforms of Human Immunoglobulin E Proteins. *J. Biol. Chemistry*. 271:3428-36, 1996.
136. Diaz-Sanchez, D., Tsien, A., Casillas, A., Dotson, A.R., **Saxon, A.** Enhanced Nasal Cytokine Production in Human Beings after *in vivo* Challenge with Diesel Exhaust Particles. *J. Allergy Clin. Immunol.*, 98:114-23, 1996.
137. Fujieda, S., Waschek, J.A., Zhang, K., **Saxon, A.** Vasoactive intestinal peptide induces Sa/Sm switch circular DNA in human B cells, *J. Clin. Invest.* 98:1527-32, 1996.
138. Fujieda, S., Lin, Y.Q., **Saxon, A.**, and Zhang, K. Multiple Types of Chimeric Germ-line Ig Heavy Chain Transcripts in Human B Cells: Evidence for *trans*-splicing of Immunoglobulin RNA. *J. Immunol.*, 157: 3450-9, 1996
139. Peterson, B. and **Saxon A.** Global Increases in Allergic Respiratory Disease: The Possible Role of Diesel Exhaust. *Ann. All. Asthma, Immunol.* 77:263-8, 1996.
140. Fujieda, S., **Saxon, A.**, Zhang, K., Direct Evidence that g1 and g3 switching in human B cells is interleukin-10 dependent.. *Molecular Immunology*. 1335-43, 1997.
141. Tsien, A., Diaz-Sanchez, D., **Saxon, A.** The Organic Component of Diesel Exhaust Particles and Phenanthrene, a Major Polyaromatic Hydrocarbon Constituent, Enhance IgE Production by IgE- secreting EBV-transformed Human B cells *in vitro*. *Toxicology and Applied Pharmacology*. 142:256-63, 1997.
142. **Saxon, A.** Diaz-Sanchez, D., Zhang, K. Regulating expression of distinct human secreted IgE proteins produced by alternative RNA splicing. *Biochemical Society Transactions* 25:383-387, 1997.
143. Diaz-Sanchez, D., Tsien, A, Fleming, J., **Saxon, A.** Combined Diesel Exhaust Particulate and Ragweed Allergen Challenge Markedly Enhances In Vivo Nasal Ragweed-Specific IgE and Skews Cytokine Production to a TH2-Type Pattern, *J. Immunol*, 158:2406-2413, 1997.
144. Thompson, AA, Talley, JA, Do, HN, Kagan, HL, Kunkel, L, Berenson, J, Cooper, M., **Saxon, A.**, Wall, R. Aberrations in the B cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. *Blood*. 90:1387-94, 1997.
145. Ng, D, Kokot, N, Faris, M, **Saxon, A.** Nel, A. Macrophage activation by polycyclic aromatic hydrocarbons: Evidence for the involvement of stress-activation protein kinases. AP-1 and anti-oxidant response elements. *J. Immunol*. 161:942-951, 1998
146. Fujieda, S, Sieling, P.A., Modlin, R.L., **Saxon, A.** CD1b-restricted T cells influence IgG subclass and IgE production, *J. Allergy Clin. Immunol.* 101:545-51, 1998.
147. Wakim, M, Alazard, M, Yajima, A, Speights, D, **Saxon, A.** Steihm, ER. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. *Ann. Allergy, Asthma, Immunol.* 83: 53-58, 1998.

148. Fujieda, S. Diaz-Sanchez, D., **Saxon, A.** Combined Nasal Challenge with Diesel Exhaust Particles and Allergen Induces In Vivo IgE Isotype Switching. *Am. J. Respir. Cell Mol. Biol.* 19: 507-512. 1998
149. Nel, A.E. Diaz-Sanchez, D. Ng, D. Hiura, T. **Saxon, A.** Enhancement of allergic inflammation by the interaction between diesel exhaust particles and the immune system. *J. Allergy Clin. Immunol.* 102:539-554. 1998.
150. Wang, M., **Saxon, A.**, Diaz-Sanchez, D. Early IL-4 production driving Th2 differentiation in a human in vivo model is mast cell derived. *Clinical Immunology.* 90:47-54. 1999.
151. Thompson, A.A. Do, H.N. **Saxon, A.**, Wall, R. Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia. *Leukemia and Lymphoma.* 35:561-9. 1999.
152. Diaz-Sanchez, D. Tsien, A. Flemming, J. **Saxon, A.** Effect of topical fluticasone propionate on the mucosal allergic response induced by ragweed allergen and diesel exhaust particle challenge. *Clinical Immunology* 90:313-320. 1999.
153. **Saxon, A.**, Nel, A.E., Diaz-Sanchez, D. Diesel particulates in allergic airway disease. *Jap. J. Rhinology* 38:123-8. 1999.
154. Diaz-Sanchez, D. Wang, M. Penichet-Garcia, M. Jyrala, M., **Saxon, A.** Nasal challenge with diesel exhaust can induce sensitization to a neoallergen in the human mucosa. *J. Allergy Clin. Imm.* 104:1183-8. 1999.
155. **Saxon, A.**, Ownby, D., Huard, T., Parsad, R., Roth H.D. Prevalence of IgE to Natural Rubber Latex in unselected blood donors and performance characteristics of Alastat® testing. *Annals of Allergy, Asthma and Immunology.* 84:199-206, 2000.
156. Geha, R.S. Beiser, A. Ren, C. Patterson, R. Greenberger, P.A. Grammer, L.C. Ditto, A.M. Harris, K.E. Shaughnessy, M.A. Yarnold, P.R. Corren, J. **Saxon, A.** Multicenter, double-blind placebo controlled multiple challenge evaluation of reported reactions to monosodium glutamate. *J. Allergy Clin Imm.* 106:973-980. 2000.
157. Diaz-Sanchez, D. Jyrala, M. Ng, D. Nel, A.E., **Saxon, A.** *In vivo* challenge with diesel exhaust particles enhances expression of the C-C chemokines Rantes, MIP-1a and MCP-3 in humans. *Clinical Immunology.* 97: 140-5. 2000
158. Diaz-Sanchez D. Penichet-Garcia M, **Saxon A.** Diesel exhaust particles directly induce activated mast cells to degranulate and increase histamine levels and symptom severity. *J Allergy Clin Immunol.* 2000 Dec;106(6):1140-6.
159. Chan, L. Lyczak, J.B. Zhang, K. Morrison, S. **Saxon, A.** The novel human IgE epsilon heavy chain, epsilon tailpiece, is present in plasma as part of a covalent complex. *Molecular Immunology*, 37:241-52. 2001
160. Heo, Y., **Saxon, A.**, and Hankinson, O. Effect of diesel exhaust particles and their components on the allergen-specific IgE and IgG1 response in mice. *Toxicology.* 159: 143-158. 2001.
161. Diaz-Sanchez, Penichet-Garcia, M, **Saxon, A.** Differential effects diesel exhaust particle chemicals vs the carbon core human allergic responses. *Immunology* 107: 55-61. 2002
162. Zhang, K., Zhang, L., Yamada, T, Vu M.V., Lee, A. **Saxon A.**, Efficiency of I ϵ promoter-directed switch recombination in GFP expression based switch constructs works synergistically with other promoter and/or enhancer elements but is not tightly linked to the strength of the transcriptional activity. *European J. Immunol.* 32:424-34. 2002
163. Zhu, D.C. Kepley, C.L. Zhang, M, Zhang, K, **Saxon, A.** A Novel Human Ig Fc γ -Fc ϵ Bifunctional Fusion Protein Inhibits Fc ϵ RI-Mediated Degranulation. *Nature Medicine* 8:518-22. 2002.
164. Devouassoux, G., **Saxon, A.**, D.D. Metcalfe D.D., Prussin, C. Colomb, M.G., Brambilla, C., Diaz-Sanchez, D., Chemical Constituents of Diesel Exhaust Particles Induce IL-4 Production by Human Basophils. *J. All. Clin. Imm.* 109:847-853. 2002.

165. Yamada T, Zhu D, **Saxon A**, Zhang K. CD45 controls interleukin-4-mediated IgE class switch recombination in human B cells through its function as a Janus kinase phosphatase. *J Biol Chem*. 2002 Aug 9;277(32):28830-5
166. Zhang K, Zhang L, Zhu D, Bae D, Nel A, **Saxon A**. CD40-mediated p38 mitogen-activated protein kinase activation is required for immunoglobulin class switch recombination to IgE. *J Allergy Clin Immunol*. 2002 Sep;110(3):421-8.
167. Zhou, C, **Saxon, A** and Zhang K.. Human Activation-Induced Cytidine Deaminase is induced by IL-4 and negatively regulated by CD45: Implication for CD45 as a Janus Kinase Phosphatase in Antibody Diversification. *J. Immunol.* 170. 1887-1893. 2003.
168. Kepley, CL, Zhang, K, Zhu, DC, **Saxon, A**: FcεRI-FcγRII Co-Aggregation Inhibits IL-16 Production From Human Langerhans-Like Dendritic Cells. *Clin Imm*. 108(2):89-94. 2003.
169. Yamada, T, Zhu, DC, Zhang, K, **Saxon, A**. Inhibition of IL-4-induced class switch recombination by a human Ig Fc gamma -Fc epsilon chimeric protein. *J. Biol. Chem*. 278:32818-32824. 2003.
170. Gilliland, FD, Li YF, **Saxon, A** Diaz-Sanchez, D. Glutathione-S-Transferase M1 and P1 Genotypes Protect Against Xenobiotic Enhancement of Allergic Responses. *Lancet*. 363:119-125. 2004.
171. Bastain, TM, Frank D, Gilliland, FD, Li, YF., **Saxon, A**, Diaz-Sanchez, D. Intra-Individual Reproducibility of Nasal Allergic Responses to Diesel Exhaust Particles Indicates a Susceptible Phenotype. *Clin. Immun*. 109:130-6. 2004.
172. Kepley, CL, Taghavi, S, Mackay, G, Zhu, D, Morel, PA, Zhang, K, Ryan, JJ, Satin, LS, Zhang, M, Pandolfi, PP and **Saxon, A**. Co-Aggregation of FcγRII With FcεRI on Human Mast Cells Inhibits Antigen-Induced Secretion and Involves SHIP-Grb2-Dok Complexes. *J. Biol. Chem*. 279:35139-49. 2004.
173. Corren J, Diaz-Sanchez D, **Saxon A**, Deniz Y, Reimann J, Sinclair D, Davanecaze T, Adelman D. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. *Ann Allergy Asthma Immunol*. 93:243-8. 2004.
174. Zhang, K, Kepley, CL, Terada, T, Daocheng Zhu, DC, PhD, Perez, H, **Saxon, A**. Inhibition of Allergen Specific IgE Reactivity by a Human Ig Fcγ-Fcε Bifunctional Fusion Protein. *J Allergy Clin Immunol*. 114:321-7. 2004.
175. Zhu, D, Kepley, CL, Zhang, K, Terada, T, Yamada, T, **Saxon, A**. A Chimeric Human –Cat Fusion Protein Blocks Cat-induced Allergy. *Nature Medicine*. 11:446-9. 2005.
176. Yamada, T, Zhang, K, Yamada, A, Daocheng Zhu, D, **Saxon A**., Lymphocyte Stimulator activates p38 MAPK in Human Ig Class Switch Recombination. *Amer. J. Resp. Cell Mol. Biol*. 32: 388-94. 2005.
177. Riedl, MA, Landaw, EM, **Saxon A**, Diaz-Sanchez, D. Initial High-dose Nasal Allergen Exposure Prevents Allergic Sensitization to a Neoantigen. *J Immunol*, 174:7440-5. 2005
178. Terada, T, Zhang, K, Belperio, J, Londhe, V, **Saxon A**.. A chimeric human-cat Fcγ-Fcε d1 fusion protein inhibits systemic, pulmonary and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1, the major cat allergen. *Clinical Immunology*. 120:45-56. 2006.
179. Saxon A, Zhu D, Zhang K, Chan LA, Kepley CL. Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases. *Arb Paul Ehrlich Inst. Bundesamt Sera Impfstoffe Frankf AM*. 2006;(95):223-31
180. St. Clair, W.E, Larry A, Turka, L.A., Saxon, A., Jeffrey B, Matthews, JB., Sayegh, MH, Eisenbarth, GS, Bluestone, J., New Reagents on the Horizon for Immune Tolerance. *Annual Review of Medicine*, 2007. 58:329-46

181. Zhang K, Zhu D, Kepley C, Terada T, Saxon A. Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy. *Immunol Allergy Clin North Am*. 27:93-103. 2007.
182. Allen L, Kepley C, Saxon A, Zhang K. Modifications to a Fcγ-Fcε fusion protein alter its effectiveness in the inhibition of FcεR1-mediated functions. *J. Allergy Clin. Immunol*;120:462-8. 2007
183. Mertsching, E, Bafetti, L, Hess, H, Stuart Perper, S, Giza, K, Allen, L, Negrou, E, Hathaway, K, Hopp, J, Chung, J, Daniel Perret, D, Michael Shields, M, **Saxon, A** and, Kehry, MR. A mouse FcγFcε protein that inhibits mast cells through activation of FcγRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases. *J. Allergy Clin. Immunol*. 121: 441-447. 2008
184. **Saxon, A**, Kepley, C, Zhang, K. "Accentuate the negative, eliminate the positive": Engineering allergy therapeutics to block allergic reactivity via negative signaling. *J. Allergy Clin. Immunol*. 121: 320-5. 2008.
185. Riedl, MA, **Saxon, A**, Diaz-Sanchez, D. Oral Sulforaphane increases Phase II antioxidant enzymes in the human upper airway. *Clin Immunol*, 130:244-51. 2009.
186. Behnecke, B., Wei L., Chen L., **Saxon, A.**, Zhang, K. A Chε-Based Allergen Gene Vaccine Platform That Targets Human Antigen Presenting Cells via the High Affinity IgE Receptor (FcεR1). *J. Allergy Clinical Immunology*;124:108-13, 2009.

Papers in Press

187. Zhang, K., Behnecke, A., Chen, L., **Saxon, A** and Li W. An IgE-based Polyplex Allergen Gene Vaccine That Targets Dendritic Cells: A Novel Therapeutic Approach for Severe Food Allergy. in press. *Int. Arch. Allergy*.
188. Zhang K., Behnecke, A., Li, W., **Saxon, A**. A novel multi-potential dendritic cell targeted gene vaccination platform; application to food allergy and beyond. In press. Arb Paul Ehrlich Inst. Bundesamt Sera
189. Lin E., **Saxon A**, Riedl M., Penicillin Allergy: Value of Including Amoxicillin as a Determinant in Penicillin Skin Testing *Int. Arch All Imm.* in press.

Research Papers - non-peer reviewed

190. Gale, R.P., Opelz, G., Mickey, M.R., Graze, P.R. and **Saxon, A**. Immunodeficiency following allogeneic bone marrow transplantation. *Transplant Proc*. 10:223. 1978.
191. Opelz, G., Gale, R.P., Feig, S.A., Walker, J., Terasaki, P.I. and **Saxon, A**. Significance of HLA and non-HLA antigens in bone marrow transplantation. *Transplant Proc*. 10:43. 1978.
192. **Saxon, A**. and Stevens, R.H. Synthesis of human IgE *in vitro* in normals and high IgE atopy. *Int Archs Allergy Appl Immunol*. 66:55. 1981.
193. **Saxon, A.**, Mawhinney, H. and Stevens, R.H. Alterations in functional human B cell subsets that produce IgG and IgE *in vitro* by repeated antigen exposure *in vivo*. In: Human B cell function: activation and regulation. A.S. Fauci and R.P. Baillieux, eds. Raven Press. 1982. p.73.
194. Denis, K.A., Wall, R. and **Saxon, A**. Human-human hybridomas in the study of immunodeficiencies. In: Human hybridomas and monoclonal antibodies. Engleman, Fong, Larrack and Raubitschek, eds., Plenum Pub. Co., New York. 1985. p. 293.
195. Kimata, H. and **Saxon, A**. Natural killer cell interaction with IgE in the control of ongoing human IgE synthesis. *Int Arch Appl Immunol*. 82:419. 1987.

196. Sherr, E. and **Saxon, A.** Fc epsilon receptor mediated suppression: A mechanism for the suppression of ongoing IgE synthesis. *Int Arch Appl Immunol.* 82:414, 1987.
197. **Saxon, A.** and Kimata, H. Human Natural Killer cells and their Fc epsilon receptors in the regulation of IgE and other immunoglobulin isotypes. In: Advances in the Biosciences (Allergy and Molecular Biology). El Shami, A.S. and Merrett, T. G. (eds.), 74:359, 1989.
198. Stevens, R.H., Brieva, J.A., Martin, R.A. and **Saxon, A.** Regulation of specific antibody production via CD23. In: Monographs in Allergy, Gordon, J., (ed.), Switzerland, p. 169-177, 1991.
199. **Saxon, A.**, Zhang, K., Max, E.E. Regulation of human B cell production of IgE proteins. *Proc 9th Sandoz Immunopharmacology Symposium*, 1991.
200. Braun, J., **Saxon, A.**, Wall, R., and Morrison, S.L. The second century of the antibody: Molecular perspectives in regulation, pathophysiology, and therapeutic applications. *Western J. Med.* 157:158-168, 1992.
201. **Saxon, A.**, Zhang, K., and Max, E.E. Human ϵ mRNAs using membrane sequence encode for two membrane forms of IgE and a novel second secreted IgE. In: *Transactions of the Association of American Physicians*, Baltimore, MD, 93-99, 1992.
202. Storek, J. and **Saxon, A.** Reconstitution of B-cell immunity following bone marrow transplantation. *Bone Marrow Transplant.* 9:395-408, 1992.
203. **Saxon, A.**, Max, E.E., Diaz-Sanchez, D., Zhang, K. Alternative RNA Splicing of Epsilon Transcripts Produces mRNAs Encoding Two Membrane and Four Secreted IgE Isoforms. *Int. Arch. All. Immunol.*, 107: 45-47, 1995.
204. Diaz-Sanchez, D., **Saxon, A.** The Effect of Diesel Exhaust Particles on Allergic Disease, *Allergy & Clinical Immunology International* 8:57-61, 1996.
205. Geha RS; Beiser A; Ren C; Patterson R; Greenberger PA; Grammer LC; Ditto AM; Harris KE; Shaughnessy MA; Yarnold PR; **Saxon A.** et al. Review of alleged reaction to monosodium glutamate and outcome of a multicenter double-blind placebo-controlled study. *Journal of Nutrition*. 2000 Apr; 130(4S Suppl):1058S-62S.
206. **Saxon, A.** and Diaz-Sanchez, D. Diesel Exhaust as a Model Xenobiotic in Allergic Inflammation. *Immunopharmacology*, 48: 325-9, 2000.

Reviews and Book Chapters

207. **Saxon, A.** Dendrochronology. *Science in Archaeology*. 7:4, 1967.
208. **Saxon, A.** Immediate hypersensitivity: Approach to diagnosis. In Manual of Allergy and Clinical Immunology. Fisher, T.J., Lawlor, G. (eds.), Little Brown Co. Boston, 1981, p. 15.
209. **Saxon, A.** Assessment of T-cell help and suppression of B-cell function. In: Manual of Clinical Immunology. Rose, N.R. and Friedman, H. (eds.), Amer Soc Micro. Washington, D.C. 1980, p. 151.
210. Wall, R. and **Saxon, A.** Molecular approaches to human immune functions and disorders. In: Genetic Disease: Diagnosis and Treatment. Dietz, A.A. (ed.). Amer Assoc Clin Chem. Washington, D.C. 1983, p. 131.
211. **Saxon, A.** Immediate hypersensitivity reactions to beta-lactam antibiotics. *Rev of Inf Dis*. 5:5368, 1983.
212. **Saxon, A.** Insect allergy. In: Allergy and Clinical Immunology. Beall, G. (ed.). John Wiley and Sons Inc, New York City. 1983, p. 201.
213. Thompson, L.F., **Saxon, A.**, O'Connor, R. and Fox, R. Ecto-5'- nucleotidase as a cell surface marker of human T lymphocyte subpopulations. In: Intercellular Communication in Leukocyte Function. Parker, J.W. and O'Brien, R.L. (eds.). Wiley and Sons, New York City. 1983, p. 189.

214. Adkinson, N.F., Saxon, A., Spence, M.R. and Swabb, E.A. Cross-allergenicity and immunogenicity of aztreonam. *Rev Inf Disease*. 7:613. 1983.
215. Saxon, A. Reconstitution of specific immunity following bone marrow transplantation. UCLA Symposium on Molecular and Cellular Biology. Gale, R.P. and Chaplin, R. (eds.). Alan R. Liss, Inc. *Progress in Bone Marrow Transplantation*. 53:623-633. 1987.
216. Saxon, A. and Stiehm, R. The B cell system. In: Immunologic Disorders in Infants and Children. Stiehm, E.R. (ed). W.B. Sanders Co. 1988.
217. Saxon, A. Immediate hypersensitivity: Approach to diagnosis. In: Manual of Allergy and Clinical Immunology. Fisher, T.J. and Lawlor, G. (eds.). Little Brown Co. Boston. 2nd Edition. 1987.
218. Saxon, A., Beall, G., Rohr, A. and Adelman, D. Immediate hypersensitivity reactions to beta-lactam antibiotics. *Annals of Int Med*. 107:204. 1987.
219. Adelman, D.C. and Saxon, A. Recurrent bacterial infections and cellulitis in a 29 year old woman with a history of hypogammaglobulinemia. *Ann Allergy*. 59:403. 1987.
220. Saxon, A. Antibiotic choices in the penicillin allergic patient. *Postgraduate Medicine*. 83:135. 1988.
221. Saxon, A. and Kaplan A. Immediate hypersensitivity. *Immunology and Allergy Clinics of North America*. 8:145. 1988.
222. Saxon, A. and Campen, V. AIDS: State of the art. spring 1988. *J Allergy Clin Immunol*. 81:796. 1988.
223. Saxon, A. Aztreonam in the management of gram-negative infections in penicillin allergic patients: A review. *Ped Infec Dis.J*. 8: 124. 1989.
224. Storek, J and Saxon, A. Reconstitution of B-cell immunity following bone marrow transplantation. *Bone Marrow Transplant*. 1992. 9:395-408.
225. Saxon, A. Immunodeficiency: Functional B-cell Studies. In: Manual of Clinical Laboratory Immunology. Rose, N.R., Friedman, H. and Fahey, J.L. (eds.). Amer Soc Micro. Washington, D.C. 1992, p 403-8.
226. Adelman, D and Saxon, A. Immediate hypersensitivity: Approach to diagnosis. In: Manual of Allergy and Clinical Immunology. Lawlor, G. and Adelman, D. (eds.). Little Brown Co. Boston, 3rd Edition. 1994. p 18-39.
227. Saxon, A., Diaz-Sanchez, D., Zhang, K., The Allergic Response in Host Defense. In Clinical Immunology. R.R. Rich, T.A. Fleisher, B.D. Schwartz, W.T. Shearer, and W. Strober. (eds.) Mosby Co. St. Louis, MO., p 847-62. 1996.
228. Zhang, K. and Saxon, A., Human IgE: Production of a family of IgE proteins by alternative splicing of the 3' end c RNA. in Molecular Mechanisms of IgE Regulation. Vercelli, D. (ed), Wiley & Sons, London, p191-205-224. 1997
229. Zhang, K. and Saxon, A., Human IgE: Isotype switching from μ to ϵ Ig heavy chain gene in human B cells as determined by switch circle analysis. in Molecular Mechanisms of IgE Regulation. Vercelli, D. (ed), Wiley & Sons, London.191-204, 1997
230. Hardin, BD, Kelman, BJ, Saxon, A. Adverse human health effects associated with molds in the indoor environment. *J Occup Environ Med* 2003 May;45(5):470-8.
231. Saxon, A. What impact will the Immune Tolerance Network have on the future treatment of allergic diseases? *Clin Exp Allergy*. 34:1657-9. 2004.
232. Saxon, A., Zhu, D, Zhang, K, Allen, L.C., Kepley, C.L, Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases, *Current Opinion in Allergy and Clinical Immunology*. 4:563-568. 2004.
233. Saxon, A., and Diaz-Sanchez, D. Air Pollution and Allergy: You are what you breathe. *Nature Immunology*. 6:223-6. 2005.

- 234. Bush RK, Portnoy JM, **Saxon A**, Terr AI, Wood RA. AAAAI Position Paper: The medical effects of mold exposure. *J Allergy Clin Immunol*. 117:326-33. 2006.
- 235. Zhang K, Zhu D, Kepley C, Terada T, **Saxon A**. Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy. *Immunol Allergy Clin North Am*. 27:93-103. 2007.
- 236. **Saxon, A**, Zhu D, Zhang K, Chan. LA, Kepley. CL Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases.. *Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M*. 95:223-31. 2006.

Lin E., Saxon A, Riedel M

UNIVERSITY OF CALIFORNIA, LOS ANGELES -- UCLA

BERKELEY • DAVIS • IRVINE • LOS ANGELES • RIVERSIDE • SAN DIEGO • SAN FRANCISCO • SANTA BARBARA • SANTA CRUZ

ANDREW SAXON, MD
PROFESSOR OF MEDICINE, EMERITUS
CLINICAL IMMUNOLOGY AND ALLERGY
DEPARTMENT OF MEDICINE
10833 LE CONTE AVENUE, 52-175 CHS
LOS ANGELES, CALIFORNIA 90095-1680
OFFICE (310) 206-8050 FAX (310) 206-8107
EMAIL: asaxon@mednet.ucla.edu

January 1, 2010


Re: 2010 Fee Schedule Medical Legal Work

As of January 1, 2010, the fee schedule for medical legal consultation will be \$570.00 per hour except for testimony (deposition and trial) that will be \$780.00 per hour. The fee for examinations will \$580.00/hour plus the cost any laboratory or other special testing that is required.

I generally will request a fully refundable retainer of \$5000.00 at the time of engagement. While it is not required for me to begin work on the matter, it is appreciated.

Andrew Saxon, Tax ID 116-36-9214
416 15th St
Santa Monica, CA

Sincerely yours



Andrew Saxon, MD

Andrew Saxon, MD
List of Testimony 2.26.10

1. Hastenstab vs OCCSI	Mr. Gregory Hulbert, Defense Attorney Mr. Tom Rockett, Plaintiff	Deposition	6.27.06
2. Moss v. Venoco et al	Ms. Cindy Cwik, Latham & Watkins, San Diego, CA	Deposition	8.3.06
3. Hughes v. Desert Village HOA	Mr. Lane Webb, Wilson Elsner, San Diego, CA	Deposition	10.30.06
4. Hake v Coleman Homes	Mr. Griff Hayes, Cooksey Toolen, Las Vegas, NV	Deposition	11.16.06
5. Constance Acevedo, et al. v. California Spray-Chemical Company,	Ms. Ruth Kahn, Steptoe & Johnson, Los Angeles, CA	Deposition	1.4.07
6. Connie Terrell Bollinger, et al v. Michael's Cooling & Heating	Ms. Bonita Armour	Deposition	2.19.07
7. Daniels L. vs. Ocean Atlantic Development et al	Mr. Dan Webster, Webster Law, Daytona Beach Mr. Greenspan, Daytona Beach	Deposition Frye Hearing	2.21.07 3.14.07
8. Claiborne, Janice v. The Housing Authority of New Orleans	Mr. Gary Zwain,	Class certification Hearing	3.13.07
9. Wagle v. Yarnell	Mark T. Coffin, Hardin & Coffin, defense Witzer law firm, Plaintiffs	Deposition	7.12.07
10. Taylor	Carol Arnold, Wadsworth, Franklin McCall & Bevin	Trial	DATE?
11. 2077 vs. Yagoda	Mark M. Wiechnik., Stark & Stark	Trial	10.22.07
12. Brogen, C v. Pleuger	Ms. Jade Tran, Wood Smith Henning, Berman, Defense Attys	Deposition Trial	9.20.07 10.23.07
13. Paulkiwitz, V. Suburban	Derek Straastsma	Trial Trial	Sept 07 Oct 07
14. Flores, R. et al. v. Stern et al.	Birnard Bihr, Veitch Carlson, Defense Atty	Deposition	5.23.08
15. Billik vs.	Mr. Steve Testan, Mr. David Robin, Mr. Fred Kumetz	Deposition	6.17-18.08 10.17.08
16. Kasai v. Canon	Ms. Carolyn Sieve, Seyfarth Shaw	Deposition	8.27.08
17. Hensley vs. Hoss	Kevin McNaughton, Schaffer Laks	Deposition	10.24.08
18. Marshall vs. D.R. Horton	David Schneider	Arbitration	12.3.08
19. Barragan vs Pankin Gardens	Kevin Warren defense Harrington Foxx Margaret Elder Plaintiff, Law office of M. Elder	Deposition Trial	1.22.09 3.30.09
20. Walker v. Givaudan Flavor CorpCase Number. A0700446	V. Tom Meador III defense, Morgan Lewis, LA, CA Scott Hill, plaintiff, Humphrey Farrington, Independence MO	Deposition	3.31.09
21. Harris v. 3075 Wilshire LLC	J. Bacon, Archer & Norris, LA, CA Defense R. Chaskin, Chaskin Law, LA, CA Plaintiff	Deposition 402 Hearing	6.9.09 6.10.09
22. Sharp v.Kaye	P.C. Zvonicek, Gibbs & Giden, Locher, Defense	Deposition	7.16.09
23. Callahan v Goya	L.J. Pedersen, Bledsoe & Cathcart, Defense.	Deposition	7.24.09
24. Shearer v. Scheer	Jennifer Cooney, Defense, Dr. M. Morris Plaintiff.	Deposition	2.25.10



REDMOND, WA • PORTLAND, OR • HILTON HEAD, SC • CAPE ELIZABETH, ME

Bryan D. Hardin, Ph.D., Fellow, A.T.S.

**Assistant Surgeon General (Retired),
U.S. Public Health Service
and
Former Deputy Director,
National Institute for Occupational
Safety and Health**

Suite 4A PMB 344
33 Office Park Road
Hilton Head Island, SC 29928

Telephone: 843-363-9466
Facsimile: 843-363-9465
Cell: 843-422-2197
E-Mail: bhardin@veritox.com



EDUCATION

- Ph.D. Environmental Health Sciences, Division of Graduate Studies and Research, University of Cincinnati, 1983
- M.S. Zoology, College of Arts and Sciences, University of Oklahoma, 1972
- B.S. Zoology, College of Arts and Sciences, University of Oklahoma, 1970
- B.S. Mathematics, College of Arts and Sciences, University of Oklahoma, 1966

PROFESSIONAL EXPERIENCE

- | | |
|------------------------|--|
| July 2004 – Present | Veritox, Inc. (formerly GlobalTox, Inc.)
Principal |
| June 2001 – June 2004 | GlobalTox, Inc.
Senior Consultant / Practice Leader |
| July 2000 – June 2003 | Bryan Hardin Consulting |
| April 1998 - June 2000 | National Institute for Occupational Safety and Health (NIOSH)
Deputy Director
Atlanta, GA |



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

PROFESSIONAL EXPERIENCE (continued)

September 1996 - April 1998	Office of the Director, NIOSH Lead Senior Scientist Washington, DC
January 1996 - August 1996	NIOSH Acting Deputy Director Atlanta, GA
October 1994 - August 1996	Office of the Director, NIOSH Senior Scientist Washington, DC
September 1993 - September 1994	Office of the Assistant Secretary of Labor for Occupational Safety and Health (OSHA), US Department of Labor Special Assistant (on detail from NIOSH) Washington, DC
April 1992 - September 1993	NIOSH Assistant Director and Director of the Washington Office Washington DC
April 1990 - March 1992	Division of Standards Development and Technology Transfer, NIOSH Deputy Director (Acting June 1989 - April 1990) Cincinnati, OH
December 1987 - April 1990	Document Development Branch. Division of Standards Development and Technology Transfer, NIOSH Chief Cincinnati, OH
February 10 - May 15, 1988	Office of the Director, NIOSH Acting AIDS Coordinator Atlanta, GA
October 1986 - November 1987	Office of the Director, Division of Standards Development and Technology Transfer, NIOSH Senior Reviewer (Chief, July 1987 - November 1987) Cincinnati, OH
September 1977 - September 1986	Acute and Subchronic Toxicology Section, Experimental Toxicology Branch, Division of Biomedical and Behavioral Science, NIOSH Research Biologist Cincinnati, OH



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

PROFESSIONAL EXPERIENCE (continued)

August 1975 - August 1977 **Environmental Health Sciences, Kettering Laboratory,
University of Cincinnati Medical Center**
US Public Health Service Graduate Trainee
Cincinnati, OH

July 1972 - August 1975 **Criteria Development Branch, Office of Research and
Standards Development, NIOSH**
Criteria Manager (Chief, Group B, January - August 1975)
Rockville, MD

UNIFORMED SERVICE

1972 - 2000: Commissioned Officer, United States Public Health Service. Highest rank: Assistant Surgeon General (O-7, Rear Admiral) Assimilated into Regular Corps 1 July 1975.

1968 - 1972: US Army Reserve. Administrative Officer, Headquarters, 95th Division (Training), Oklahoma City, OK. Highest Rank: Captain (O-3, Adjutant Generals Corps)

1966 - 1968: US Army. Electronics Research and Development Activity, White Sands Missile Range, NM. Administrative Officer; Personnel Officer; Commanding Officer, Headquarters and Headquarters Company. Highest rank: First Lieutenant (O-2, Adjutant Generals Corps)

ACADEMIC APPOINTMENTS

2000 - 2006 **Rollins School of Public Health, Emory University,
Atlanta, GA**
Department of Environmental and Occupational Health
Adjunct Associate Professor

1971 - 1972 **Department of Zoology, University of Oklahoma, Norman, OK**
Graduate Research Assistant

1970 - 1971 **Department of Zoology, University of Oklahoma, Norman, OK**
Graduate Teaching Assistant in Human Physiology

PROFESSIONAL AFFILIATIONS

American College of Occupational and Environmental Medicine

American College of Toxicology

American Industrial Hygiene Association

AIHA Journal Editorial Advisory Group, 1995-2000

Emergency Response Planning Committee, 2001-Present



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

PROFESSIONAL AFFILIATIONS (continued)

Society of Toxicology

Councilor, Occupational & Public Health Specialty Section, elected May 2004-2006

Teratology Society

Public Affairs Committee, 1985-1988

Constitution and Bylaws Committee, 1993-1996 (Chair 1995-1996)

HONORS AND PROFESSIONAL RECOGNITION

Fellow, Academy of Toxicological Sciences, 2005 - Present

Recipient: "Distinguished Service Award" from the International Safety Equipment Association, (ISEA): November 7, 2001

Named US Public Health Service "Career Scientist of the Year," June 8, 1999

Named "Professional/Scientific Federal Employee of the Year" by the Greater Cincinnati Federal Executive Board and Federal Business Association, June 7, 1983

US Public Health Service Commissioned Corps:

Exceptional Capability Promotion: November 1974; January 1989

Distinguished Service Medal: January 2001

Surgeon General's Exemplary Service Medal: June 1993, January 1997

Outstanding Service Medal: June 1985

Commendation Medal: April 1981; November 1987; October 1997

PHS Citation: December 1990

Unit Commendation Medal: May 1987; February 1989; January 1991; June 1994, June 1996, October 1996; October 1999

Special Assignment Service Ribbon: July 1987, January 1994

Bicentennial Unit Commendation, January 1999

Finalist for 1988 Alice Hamilton Science Award for Excellence in Occupational Safety and Health

Research Advisor for National Research Council Associateship Program

Phi Sigma International Honorary Biological Society

Sigma Xi: The Scientific Research Society

Biographical profile in:

Who's Who in Frontiers of Science and Technology, 2nd Ed., 1985

Who's Who in the Midwest, 23rd Ed., 1991; 24th Ed., 1993

Who's Who in Science and Engineering, 2nd Ed., 1993 through 6th Ed., 2002

Men of Achievement, 16th Ed., 1993

Who's Who in the East, 25th Ed., 1994

Who's Who in the World, 12th Ed., 1994

Who's Who in Medicine and Healthcare, 2nd Ed., 1999 through 6th Ed., 2006

Who's Who in America, 55th Ed., 2001 through 60th Ed., 2006



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

FEDERAL COURT, ADMINSTRATIVE PROCEEDINGS AND CONGRESSIONAL HEARINGS

Witness for NIOSH in United States District Court for the Western District of Louisiana, Lafayette-Opelousas Division, in Methane Awareness Resource Group et al. v. United States of America et al. (lawsuit challenging NIOSH and NCI scientific peer review of an epidemiologic study of lung cancer in diesel-exposed underground miners), April 16 and 17, 1997.

Lead witness (Logging, Walking & Working Surfaces, Hazardous Waste, Vehicle Safety, Glycol Ethers, Respiratory Protection, Tuberculosis) or member of CDC/NIOSH testimony team (Bloodborne Disease) at public hearings for proposed OSHA regulations.

Lead witness for DHHS at hearing conducted by the Ad Hoc Subcommittee on Consumer and Environmental Affairs of the Senate Committee on Government Affairs, presenting testimony on potential health risks of police radar guns, August 10, 1992.

Witness for the DHHS Office of General Council at an arbitration hearing, presenting testimony pertaining to the NIOSH CIB #54 on Environmental Tobacco Smoke, San Francisco, CA, November 15, 1991.

Expert witness at an Administrative Law contest of an OSHA citation for exposure to "coal tar pitch volatiles." April 25-27, 1978.

PUBLICATIONS

(A) = Peer Reviewed (B) = Government Reports & Book Chapters (C) = Abstracts & Letters

- 1 (B) Criteria for a Recommended Standard. 1973. Occupational Exposure to Coke Oven Emissions. US Department of Health Education and Welfare, NIOSH.
- 2 (B) Criteria for a Recommended Standard. 1973. Occupational Exposure to Inorganic Arsenic. US Department of Health Education and Welfare, NIOSH.
- 3 (B) Criteria for a Recommended Standard. 1973. Occupational Exposure to Chromic Acid. US Department of Health Education and Welfare, NIOSH.
- 4 (A) Gehrs, C.W., Hardin, B.D. 1974. Production of resting eggs by Diaptomus clavipes Schacht (Copepoda, Calanoida). The American Midland Naturalist 91:486-488.
- 5 (B) Robertson, A., Gehrs, C.W., Hardin, B.D., Hunt, G.W. 1974. Culturing and ecology of Diaptomus clavipes and Cyclops vernalis. Ecological Research Series, EPA-660/3-74-006, Environmental Protection Agency.
- 6 (B) Criteria for a Recommended Standard. 1974. Occupational Exposure to Ammonia. US Department of Health Education and Welfare, NIOSH.
- 7 (B) Criteria for a Recommended Standard. 1975. Occupational Exposure to Xylene. US Department of Health Education and Welfare, NIOSH.



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

PUBLICATIONS (continued)

- 8 (B) Criteria for a Recommended Standard. 1975. Occupational Exposure to Inorganic Arsenic-New Criteria 1975. US Department of Health Education and Welfare, NIOSH.
- 9 (A) Hardin, B.D., Manson, J.M. 1980. Absence of dichloromethane teratogenicity with inhalation exposure in rats. *Toxicology and Applied Pharmacology* 52:22-28.
- 10 (A) Hardin, B.D., Bond, G.P., Sikov, M.R., Andrew, F.D., Beliles, R.P., Niemeier, R.W. 1981. Testing of selected workplace chemicals for teratogenic potential. *Scandinavian Journal of Work, Environment, and Health* 7 (Suppl 4): 66-75.
- 11 (C) Andrew, F.D., Montgomery, L.F. Sikov, M.R., Hardin, B.D. 1981. Effects of inhalation exposure to ethoxyethanol on pregnant rats and rabbits. *The Toxicologist* 1(1):30.
- 12 (A) Schuler, R.L., Hardin, B.D., Niemeier, R.W. 1982. *Drosophila* as a tool for the rapid assessment of chemicals for teratogenicity. *Teratogenesis, Carcinogenesis, Mutagenesis* 2(3-4):293-301.
- 13 (A) Hardin, B.D., Niemeier, R.W., Smith, R.J., Kuczuk, M.H., Mathinos, P.R., Weaver, T.E. 1982. Teratogenicity of 2-ethoxyethanol by dermal application. *Drug and Chemical Toxicology* 5(3):277-294.
- 14 (C) Hardin, B.D., Niemeier, R.W., Kuczuk, M.H., Mathinos, P.R., Weaver, T.E. 1982. Teratogenicity of 2-ethoxyethanol by dermal application. *Teratology* 25(2):46.
- 15 (C) Hardin, B.D. 1982. Reproductive toxicity of the glycol ethers. *J Occupational Medicine* 24(4):332-3.
- 16 (A) Hardin, B.D. 1983. Reproductive toxicology of the glycol ethers. *Toxicology* 27(2):91-102.
- 17 (A) Hardin, B.D., Niemeier, R.W., Sikov, M.R., Hackett, P.L. 1983. Reproductive-toxicologic assessment of four epoxides-Ethylene oxide, propylene oxide, butylene oxide, and styrene oxide. *Scandinavian Journal of Work, Environment, and Health* 9(2):94-102.
- 18 (A) Hardin, B.D., Schuler, R.L., McGinnis, P., Niemeier, R.W., Smith, R.J. 1983. Evaluation of propylene oxide for mutagenic activity in three in vivo test systems. *Mutation Research* 117(3-4):337-44.
- 19 (B) Schuler, R.L., Hardin, B.D., Niemeier, R.W. 1983. Investigation of Drosophila for Teratogenic Screening, in F. Homburger (Ed.), Safety Evaluation and Regulation of Chemicals, S. Karger, Basel, pp 270-276.
- 20 (A) Andrew, F.D., Hardin, B.D. 1984. Developmental effects of inhalation exposure of gravid rabbits and rats to ethylene glycol monoethyl ether. *Environmental Health Perspectives* 57:13-23.



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

PUBLICATIONS (continued)

- 21 (A) Hardin, B.D., Goad, P.T., Burg, J.R. 1984. Developmental toxicity of four glycol ethers applied cutaneously to rats. *Environmental Health Perspectives* 57:69-74.
- 22 (A) Schuler, R.L., Hardin, B.D., Niemeier, R.W., Booth, G., Hazelden, K., Piccirillo, V., Smith, K. 1984. Results of testing fifteen glycol ethers in a short-term in vivo reproductive toxicity assay. *Environmental Health Perspectives* 57:141-146.
- 23 (A) Hardin, B.D., Lyon, J.P. 1984. Summary and overview of the NIOSH Symposium on Toxic Effects of Glycol Ethers. *Environmental Health Perspectives* 57:273-275.
- 24 (B) Kimmel, C.A., LaBorde, J.B., Hardin, B.D. 1984. Reproductive and developmental toxicology of selected epoxides, Chapter 13 in Kacew S. and Reasor M.J. (Eds) Toxicology and the Newborn, Elsevier Science Publishers, pp 270 – 287.
- 25 (C) Schrader, S.M., Turner, T.W., Hardin, B.D., Niemeier, R.W., Burg, J.R. 1984. Morphometric analysis of human spermatozoa. *J Andrology* 5(1):22.
- 26 (A) Plasterer, M.R., Bradshaw, W.S., Booth, G.M., Carter, M.W., Schuler, R.L., Hardin, B.D. 1985. Developmental toxicity of nine selected compounds following prenatal exposure in the mouse: Naphthalene, p-nitrophenol, sodium selenite, dimethyl phthalate, ethylenethiourea, and four glycol ether derivatives. *Journal of Toxicology and Environmental Health* 15(1):25-38.
- 27 (A) Toraason, M., Stringer, B., Stober, P., Hardin, B.D. 1985. Electrocardiographic study of rat fetuses exposed to ethylene glycol monomethyl ether (EGME). *Teratology* 32(1):33-39.
- 28 (A) Schuler, R.L., Radike, M., Hardin, B.D., Niemeier, R.W. 1985. Pattern of response of intact *Drosophila* to known teratogens. *Journal of the American College of Toxicology* 4(4):291-303.
- 29 (C) Toraason, M., Niemeier, R.W., Hardin, B.D. 1985. Effects of ethylene glycol monomethyl ether (EGME) on maternal calcium and vitamin D metabolism during gestation. *Teratology* 31(3):58A.
- 30 (C) Hardin, B.D., Goad, P.T., Burg, J.R. 1985. Teratogenicity of diethylene glycol monomethyl ether in the rat. *Teratology* 31 (3):54A.
- 31 (C) Hardin B.D. 1985. Glycol ethers - An example of a developmental hazard. *Teratology* 31 (3):34A.
- 32 (C) Chrislip, D.W., McConnell, R.S., Hardin, B.D., Coleman, M.E. 1985. A review of human and animal research involving *N,N*-diethyl-*m*-toluamide (DEET). *Neurobehav. Toxicol. Teratol.* 7(5):527-528.
- 33 (A) Hardin, B.D., Goad, P.T., Burg, J.R. 1986. Developmental toxicity of diethylene glycol monomethyl ether (diEGME). *Fundamental and Applied Toxicology* 6:430-439.



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

PUBLICATIONS (continued)

- 34 (A) Sikov, M.R., Cannon, W.C., Carr, D.B., Miller, R.A., Niemeier, R.W., Hardin, B.D. 1986. Reproductive toxicology of inhaled styrene oxide in rats and rabbits. *Journal of Applied Toxicology* 6(3):155-164.
- 35 (A) Toraason, M., Niemeier, R.W., Hardin, B.D. 1986. Calcium homeostasis in pregnant rats treated with ethylene glycol monomethyl ether (EGME). *Toxicology and Applied Pharmacology* 86(3):197-203.
- 36 (C) Hardin, B.D., Eisenmann, C.J. 1986. Relative potency of four ethylene glycol ethers for induction of paw malformations in the CD-1 mouse. *Teratology* 33(3):85C.
- 37 (A) Hardin, B.D., Schuler, R.L., Burg, J.A., Booth, G.A., Hazelden, K.P., MacKenzie, K.M., Piccirillo, V.J., Smith, K.N. 1987. Evaluation of 60 chemicals in a preliminary developmental toxicity test. *Teratogenesis Carcinogenesis Mutagenesis* 7(1):29-48.
- 38 (A) Hardin, B.D., Eisenmann, C.J. 1987. Relative potency of four ethylene glycol ethers for induction of paw malformations in the CD-1 mouse. *Teratology* 35(3):321-328.
- 39 (A) Burg, J.R., Hardin, B.D. 1987. Recommendations for the statistical analysis of Chernoff/Kavlock test data. *Teratogenesis Carcinogenesis Mutagenesis* 7(1):49-54.
- 40 (A) Hardin, B.D. 1987. A recommended protocol for the Chernoff/Kavlock preliminary developmental toxicity test and a proposed method for assigning priority scores based on the results of that test. *Teratogenesis Carcinogenesis Mutagenesis* 7(1):85-94.
- 41 (A) Hardin, B.D., Becker, R., Kavlock, R.J., Seidenberg, J.M., Chernoff, N. 1987. Overview and Summary – Workshop on the Chernoff/Kavlock Preliminary Developmental Toxicity Test. *Teratogenesis Carcinogenesis Mutagenesis* 7(1):119-127.
- 42 (B) Hardin, B.D. (Guest Editor). 1987. Special Issue – Evaluation of the Chernoff/Kavlock Test for Developmental Toxicity, *Teratogenesis Carcinogenesis Mutagenesis* 7(1):1-127.
- 43 (B) Joint Advisory Notice. 1987. Protection Against Occupational Exposure to Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV). US Department of Labor/Department of Health and Human Services, October 19.
- 44 (A) Morrissey, R.E., Schwetz, B.A., Hackett, P.L., Sikov, M.R., Hardin, B.D., McClanahan, B.J., Decker, J.R., and Mast, T.J. 1990. Overview of reproductive and developmental toxicity studies of 1,3-butadiene in rodents. *Environmental Health Perspectives* 86:79-84.
- 45 (B) Stayner, L.T., Meinhardt, T., Hardin, B.D. 1990. Risk assessment activities of NIOSH -- Information resources and needs, in P.-Y. Lu (Ed.) *Proceedings of the Symposium on the Access and Use of Information Resources in Assessing Health Risks from Chemical Exposure*, June 27-29, Oak Ridge National Laboratory, pp 123-127.



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

PUBLICATIONS (continued)

- 46 (A) Wright, D.M., Hardin, B.D., Goad, P.T., Chrislip, D.W. 1992. Reproductive and developmental toxicity of N,N-diethyl-m-toluamide in rats. *Fundamental and Applied Toxicology* 19:33-42.
- 47 (B) Cicolella, A., Hardin, B.D., Johanson, G. 1996. Glycol ethers -- New data, new questions, in A. Cicolella, B. Hardin, and G. Johanson (Eds.) *Proceedings of the International Symposium on Health Hazards of Glycol Ethers*, 19-21 April 1994, Pont a Mousson, France., pp 1-2 in *Occupational Hygiene* 2(1-6):1-456.
- 48 (A) Hardin, B.D., Kelman, B.J., Saxon, A. 2002. Adverse human health effects associated with molds in the indoor environment: ACOEM Evidence-based Statement, October 27, <http://www.acoem.org/guidelines/article.asp?ID=52>
- 49 (A) Hardin, B.D., Kelman, B.J., Saxon A. 2003. Adverse human health effects associated with molds in the indoor environment: American College of Occupational and Environmental Medicine (ACOEM) Evidence-based Statement, *Journal of Occupational and Environmental Medicine*, 45: 470-478.
- 50 (A) Kelman, B.J., Robbins, C.A., Swenson, L.J., Hardin, B.D. 2004. Risk from inhaled mycotoxins in indoor office and residential environments. *International Journal of Toxicology*, 23:3-10.
- 51(C) Saxon, A., Hardin, B.D., Kelman, B.J. 2004. Exposure-dose-response: critical considerations in toxicology and immunology alike. *Journal of Allergy and Clinical Immunology*, 114:207.
- 52 (C) Hardin, B.D., Kelman, B.J., Brent, R. 2004. Trichloroethylene and cardiac malformations. *Environmental Health Perspectives*, 112:A607-608.
- 53 (C) Kelman, B.J., Hardin, B.D., Brent, R. 2005. Risk of teratogenicity from trichloroethylene (TCE) and dichloroethylene (DCE) in drinking water. *The Toxicologist*, 79:429.
- 54 (A) Hardin, B.D., Kelman, B.J., Brent, R. 2005 Trichloroethylene and dichloroethylene – A critical review of teratogenicity. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 73(12):931-955.
- 55 (C) Hardin, B.D., Kelman, B.J., Saxon, A. 2007 Reply to Kilburn, Gray and Kramer: *J Allergy Clin Immunol* 118(3):766-767, 2006. *J Allergy Clin Immunol* 119(1):256-257.

RECENT PRESENTATIONS

June 4, 2007: Recently published evaluations of the association of mycotoxins and health effects in indoor environments, in *Indoor Mycotoxins Update – IH Issues, Biomonitoring, Occupational Medicine*. American Industrial Hygiene Conference and Exposition, June 2-7, 2007, Philadelphia, PA.



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

RECENT PRESENTATIONS (continued)

May 9, 2007: Perchlorate – A review of animal data, in Perchlorate and Other Environmental Chemicals – Mechanistic, Clinical, and Epidemiological Studies of Effects on Thyroid function. American Occupational Health Conference, May 6-9, 2007, New Orleans, LA.

October 16 and 18, 2006: Molds in Indoor Environments – Exposure & Health Effects, in Construction Solutions, Portland, OR and Seattle, WA.

November 9, 2005: Mycotoxins and human disease in When Fungi Aren't Fun. The American College of Asthma, Allergy, and Immunology, November 4-9, 2005, Anaheim, CA.

June 16, 2005: Review of the current status of medical literature on mold. Mealey's Mold Litigation Conference, Marina del Rey, CA.

May 4, 2005: A tale of two solvents – 2-ethoxyethanol and trichloroethylene. Invited seminar at the Molecular and Environmental Toxicology Center, College of Agricultural and Life Sciences, Schools of Medicine, Veterinary Medicine, and Pharmacy, University of Wisconsin, Madison, WI.

February 16, 2005: Summary and implications of the ACOEM evidence-based statement and the IOM report on Damp Indoor Spaces and Health, in Toxicological and Occupational Medicine Perspectives on Molds and Mycotoxins – Update and Implications for IH, 2005 AIHA TeleWeb Virtual Seminar Series.

July 26, 2004: Indoor mold and human health - What is the risk? ASTM Boulder Conference on Mold in the Indoor Environment: Assessment, Health and Physical Effects, and Remediation, American Society for Testing and Materials International, July 25-30, 2004, Boulder, CO.

May 12, 2004: Summary and implications of the American College of Occupational and Environmental Medicine's evidence-based statement on adverse effects associated with molds in the indoor environment, in Roundtable 236 - Toxicological and Occupational Medicine Perspectives on Mold and Mycotoxins; Update and Implications for Industrial Hygiene, American Industrial Hygiene Conference and Exposition, May 8-13, 2004, Atlanta, GA.

May 6 and 7, 2004: T2-Mycotoxins in Bioterrorism - The Biotoxins, Uses and Abuses, sponsored by the California Association of Public Laboratories Annual Institute for Laboratorians, Sacramento (May 6, Course 060504) and Long Beach (May 7, Course 070504), California.

July 17, 2003: A scientific view of the health effects of mold, at The Growing Hazard of Mold Litigation, co-sponsored by the US Chamber of Commerce Institute for Legal Reform and the Manhattan Institute Center for Legal Policy, Washington D.C.

May 6, 2003. The toxicology of "toxic mold" in An Overview of the Issues of Indoor Mold American Occupational Health Conference, May 2-9, 2003, Atlanta, GA.



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

RECENT PRESENTATIONS (continued)

April 10, 2003: Glycol ether retrospective, Invited lecture for EHS 503b, Introduction to Toxicology, Yale Occupational and Environmental Medicine Program, New Haven, CT.

April 9, 2003: Toxic (?) Mold, Invited lecture for the Faculty and Fellows Seminar, Yale Occupational and Environmental Medicine Program, New Haven, CT.

November 16, 2000: Invited Keynote address, An overview of occupational safety and health risks – Which are greatest? General Session, American Society of Safety Engineers Symposium on Controlling Health Risks in the Workplace, November 16-17, 2000, Scottsdale, AZ.

SELECTED FEDERAL INTERAGENCY ACTIVITIES

Member, Expert Panel to Assess the Validation Status of FETAX (Frog Embryo Teratogenesis Assay) for the NIEHS/NTP Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM). February - June 2000

Member, Endocrine Disruptor Screening and Testing Advisory Committee, US EPA, November 1996 to June 1998

Member, Integrated Risk Information System (IRIS) Peer Review Panel for Vinyl Chloride, US EPA, June 3-4, 1997

Co-Chair of Surgeon General's Task Force on Clarification of the Mission and Use of the Commissioned Corps of the US Public Health Service, September - November, 1996

Committee on the Environment and Natural Resources, January 1994 - December 1996
 Subcommittee on Risk Assessment
 Subcommittee on Toxic Substances, Hazardous & Toxic Waste

Interagency Working Group on Environmental Justice, July 1994 - July 1995
 Task Force on Interagency Projects

Committee to Coordinate Environmental Health Related Programs (Chaired by the Assistant Secretary for Health, DHHS). Chairman of Task Groups charged with:

 Evaluation of the Implementation and Relevance in 1990 of "Risk Assessment and Risk Management of Toxic Substances – 1985", February to April 1990

 Review of EPA Draft Health Assessment Document for 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds Chapter 7 -- Epidemiology/Human Data, 1993

 Review of EPA Draft Health Assessment Document for 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds Chapter 9 - Risk Characterization, May to August 1994



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

SELECTED FEDERAL INTERAGENCY ACTIVITIES (continued)

TSCA Interagency Testing Committee, April 1987 to July 1989 (Vice-Chairman, 1988; Chairman, 1989)

TSCA Comprehensive Assessment Information Rule Interagency Workgroup

National Toxicology Program: Reproductive and Developmental Toxicology Work Group, responsible for coordinating NTP-sponsored reproductive research, September 1980 - September 1986

NIOSH Working Group to develop “A Proposed National Strategy for the Prevention of Work-Related Disorders of Reproduction” May 1985 to April 1987 (Chairman)

Office of Toxic Substances, EPA: Toxicology Testing Work Group to develop testing guidelines for implementation of the Toxic Substances Control Act, September to December 1978

SELECTED INTERNATIONAL ACTIVITIES

International Consultation on the International Labor Organization WorkSafe Program, Geneva, Switzerland, December 13-14, 1999.

VI Latin American Congress on Occupational Health – ALSO ‘99 / XIX Colombian Congress on Occupational Medicine and Health, Cartagena, Colombia, September 14-17, 1999 (Scientific presentation on Experimental Studies of the Reproductive Effects of the Ethylene Glycol Ethers)

Joint EU/US Conference on Health and Safety At Work, organized as a part of the Joint EU/US Action Plan under the New Transatlantic Agenda of 1995, Luxembourg, October 13-16, 1998. (Head of NIOSH delegation, session co-chair, and presenter of closing remarks for the US delegation).

International Seminar of Governmental Entities in the Area of Labor Safety and Health, sponsored by FUNDACENTRO, Ministerio do Trabalho, and International Labor Office, Brasilia (March 17-19, 1997) and Sao Paulo (March 20-21, 1997), Brazil.

International Labor Office / International Occupational Safety and Health Information Centre: Member of Steering Committee for International Hazard Datasheets on Occupations, March 1995 to 1998.

Planning and Scientific Committees for International Symposium on Health Hazards of Glycol Ethers, Co-sponsored by French INRS, Swedish NIOH, and NIOSH in Nancy, France, April 19-21, 1994. (Conference President and presenter of opening and closing remarks).



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

SELECTED INTERNATIONAL ACTIVITIES (continued)

International Agency for Research on Cancer: Member of Working Group on the Evaluation of the Carcinogenic Risk of Chemicals to Humans (drafted "Reproductive and Developmental Effects" sections of monographs):

Occupational Exposures of Hairdressers and Barbers and Personal Use of Hair Colourants; Some Hair Dyes, Cosmetic Colourants, Industrial Dyestuffs and Aromatic Amines, Lyon, October 6-13, 1992 (IARC Monographs, Volume 57).

Some Chemicals Used in Plastics and Elastomers, Lyon, June 11-18, 1985 (IARC Monographs, Volume 39).

U.S. – Mexican Joint Technical Seminar on the Iron and Steel Industry, Occupational Safety and Health Prevention Systems, Mexico City, Mexico, February 10-12, 1992.

Tri-Lateral meeting of United States, Canadian, and European Economic Community representatives regarding international harmonization of hazardous chemical labeling standards, Brussels, Belgium, April 29-30, 1991.

WHO Collaborating Centers in Occupational Health - Informal consultation of the planning group, Geneva, Switzerland, October 7-9, 1991.

World Health Organization - International Programme on Chemical Safety:

Chairman of Expert Consultation on Harmonization in Chemical Hazard Communication, Geneva, Switzerland, April 24-26, 1991.

Working Group to draft "Principles and Methods for the Assessment of Risk from Exposure to Chemicals," Carshalton, Surrey, England, February 26 to March 2, 1990.

Task Groups for Environmental Health Criteria Documents on Glycol Ethers, 1-Propanol, and 2-Propanol, Carshalton, Surrey, England, April 4-14, 1989 (Chairman of 1- and 2-Propanol Task Groups).

Coke Oven Emissions as an Occupational Health Hazard, presented at the Symposium on the Quality of the Environment and the Iron and Steel Industry, Results and Prospects, sponsored by the Commission of the European Community, 24-26 September 1974, Luxembourg, (Grand Duchy).

SELECTED PROFESSIONAL ACTIVITIES

Member, American National Standards Institute, Accredited Standards Committee Z88, Appeals Panel appointed to hear an appeal of action taken by the Z88 Respiratory Protection Committee and Z88.2 Practices for Respiratory Protection Subcommittee, May – July 2005.



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

SELECTED PROFESSIONAL ACTIVITIES (continued)

Chair, NIOSH National Occupational Research Agenda Program Review (Dermal Exposure Research Program), Tyson's Corner, VA, December 14-15, 2004.

Chair, Expert Review Panel for research proposals under the NIOSH National Occupational Research Agenda, Silver Spring, MD, July 21-22, 2004.

Member, Editorial Advisory Board, *Compliance Magazine* July 2004 – Present.

Member, Scientific Advisory Council for research program jointly sponsored by the Asphalt Institute, the Asphalt Paving Environmental Council and the Asphalt Roofing Environmental Council, 2004 – Present.

Lecturer: Health Effects of Mold, in Mold Assessment and Remediation in Buildings, periodic training course sponsored by The Environmental Institute and Compass Environmental, Inc., Marietta, GA, October 2001 - December 2003.

Co-Instructor: International Environmental Health (EOH 500), Rollins School of Public Health, Emory University, Atlanta, GA, Fall semesters 2000 and 2001.

Member, Advisory Board for the Risk Education Project, American Chemical Society, 1997 – 2000.

Member, Steering Committee, ILSI/Risk Science Institute - EPA Project on Human Variability, 1995-1997.

Ph.D. Qualifying and Dissertation Committees, Kettering Laboratory, University of Cincinnati College of Medicine.

Guest lecturer in graduate-level courses in environmental and occupational health risk assessment and policy at the University of Cincinnati, Uniformed Services University of Health Sciences, and George Washington University.

RECENT CONTINUING EDUCATION

Advanced biological sampling techniques and laboratory analysis for indoor environmental quality investigation – mold, bacteria, allergens, and all others. PDC 502. American Industrial Hygiene Conference and Exposition, June 3, 2007, Philadelphia, PA.

Allergy and Allergic Disease – A Primer for Toxicologists, AM04, Society of Toxicology Annual Meeting, March 25, 2007, Charlotte, NC.

Allergy and Allergic Disease – A Primer for Toxicologists, AM04, Society of Toxicology Annual Meeting, March 25, 2007, Charlotte, NC.



Bryan D. Hardin, Ph.D., Fellow, A.T.S.

RECENT CONTINUING EDUCATION (continued)

Physiologically Based Pharmacokinetic Modeling for Risk Assessment Applications. PM11, Society of Toxicology Annual Meeting, March 25, 2007, Charlotte, NC.

Essentials of Metal Toxicology. AM06, Society of Toxicology Annual Meeting, March 5, 2006, San Diego, CA.

Neuropathology for the Toxicologist. PM12, Society of Toxicology Annual Meeting, March 5, 2006, San Diego, CA.

The FUN of Aerosols – Fine, Ultrafine and Nano Particles in Workplace Atmospheres. PDC 427, American Industrial Hygiene Conference and Exposition, May 22, 2005, Anaheim, CA.

Welding, Manganese, and Parkinsonism. Puget Sound Occupational & Environmental Medicine Grand Rounds, University of Washington Northwest Center for Occupational Health and Safety, April 14, 2005, Seattle, WA.

Fundamentals of nanotechnology – Chemistry, exposure, health/environmental assessments and societal impacts. SR01, Society of Toxicology Annual Meeting, March 6, 2005, New Orleans, LA.

Immunology for toxicologists. AM05, Society of Toxicology Annual Meeting, March 6, 2005, New Orleans, LA.

Development and interpretation of toxicokinetic data for risk and safety assessment. PM09, Society of Toxicology Annual Meeting, March 6, 2005, New Orleans, LA.

Moisture Control, Mold and the Science Within the Building. PDC 506, American Industrial Hygiene Conference and Exposition, May 9, 2004, Atlanta, GA

Symposium: Fungal Contamination - Current Concerns and Industrial Hygiene Practice, American Industrial Hygiene Conference and Exposition, May 8, 2004, Atlanta, GA

Microorganisms in Indoor Air – Health Complaints, Sampling Strategies and Interpretation; American Industrial Hygiene Conference and Exposition, San Diego, CA, June 2, 2002.

Two-Stepping Through Toxicogenomics – A Basic Primer: Society of Toxicology Continuing Education Course, Nashville, TN, March 2002.

Mold and Mildew in Indoor Environments: American Public Health Association Continuing Education Course #1005, Atlanta, GA, October 20, 2001.

First Annual International Symposium on the Impact of Mold on Health and Indoor Air Quality, sponsored by Aerias LLC and Air Quality Sciences, Inc., Atlanta, GA, October 18-19, 2001.



VERITOX

REDMOND, WA • PORTLAND, OR • HILTON HEAD, SC • CAPE ELIZABETH, ME

Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Education and Professional Certifications

Diplomate of the American Board of Toxicology, 1980.

Renewal certification, 1985-1990.

Renewal certification, 1991-1995.

Renewal certification, 1996-2000.

Renewal certification, 2001-2005.

Renewal certification, 2006-2010.

Registered Toxicologist (United Kingdom and EUROTOX registries), 2005-2010.

Fellow, Academy of Toxicological Sciences, 2006-2011.

Post Doctoral Research Associate, University of Tennessee, Comparative Animal Research Laboratory, Oak Ridge, Tennessee, 1974-1976.

Ph.D., Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Illinois, 1975.

M.S., Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Illinois, 1971.

B.S., Department of Physiology and Biophysics, College of Liberal Arts and Sciences, University of Illinois, 1969.

Research and Administrative Appointments

1998-present	Veritox, Inc. (formerly GlobalTox, Inc.) <i>Principal and President</i>	Redmond, Washington
1994-1998	Golder Associates Inc. <i>National Director, Health and Environmental Sciences</i>	Redmond, Washington
1993-1994	Golder Associates Inc. <i>Manager, Toxicology and Risk Assessment Services</i>	Redmond, Washington
1990-1993	Failure Analysis Associates, Inc. <i>Manager, Toxicology and Managing Scientist</i>	Menlo Park, California
1989-1990	Battelle, Pacific Northwest Laboratories <i>Manager, New Projects Development, Life Sciences Center</i>	Richland, Washington
1985-1989	Battelle, Pacific Northwest Laboratories <i>Department Manager, Biology and Chemistry Department</i>	Richland, Washington
1986-1989	Battelle International Toxicology Office <i>Co-Manager</i>	
1984-1985	Battelle, Pacific Northwest Laboratories <i>Associate Department Manager, Biology and Chemistry Department</i>	Richland, Washington
1981-1983	Battelle, Pacific Northwest Laboratories <i>Section Manager, Developmental Toxicology Section, Biology Department</i>	Richland, Washington
1980-1981	Battelle, Pacific Northwest Laboratories <i>Associate Section Manager, Developmental Toxicology Section, Biology Department</i>	Richland, Washington
1979-1980	Battelle, Pacific Northwest Laboratories <i>Senior Research Scientist, Developmental Toxicology Section, Biology Department</i>	Richland, Washington
1976-1979	Comparative Animal Research Laboratory, University of Tennessee <i>Assistant Professor and Group Leader, Prenatal Toxicology Group</i>	Oak Ridge, Tennessee



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Teaching Appointments

1983-2004	New Mexico State University <i>Adjunct Professor</i>	Las Cruces, New Mexico
1979-1980	Joint Center for Graduate Studies <i>Lecturer</i>	Richland, Washington
1975-1979	Oak Ridge Associated Universities <i>Lecturer</i>	Oak Ridge, Tennessee

Professional Affiliations and Associated Appointments

Society of Toxicology (1978-present)

Program Committee, 2004-2007

Toxicology Initiative Task Force

Member, 1993-1996

Chairman, 1995-1996

Tox 90s Educational Issues Task Force, Member, 1993-1994

Ethics Committee, Member, 1991-1993

Long Range Planning Committee, Member, 1986-1987

Nominations Committee, Member, 1983

Comparative and Veterinary Specialty Section, Charter Member 1994-present

Inhalation Specialty Section, Member, 1986-present

Ethical, Legal, and Social Specialty Section

Organizing Committee Councilor, 2003-2004

Charter Member, 2005-present

Councilor, 2005-2007

Molecular Biology Specialty Section

Organizing Committee President, 1988

Charter Member, 1989-present

Founding President, 1989

Councilor, 1989-1990

Metals Specialty Section

Organizing Committee Vice President, 1980-1981

Charter Member, 1981-present

Secretary/Treasurer, 1981-1983

President-Elect, 1985-1986

President, 1986-1987

Councilor, 1987-1988

Occupational Health Specialty Section, Charter Member, 1998-present

Reproductive and Developmental Specialty Section, Charter Member, 1983-present

Risk Assessment Specialty Section, Member, 1991-1998

Northern California Chapter, Member, 1990-1993

Pacific Northwest Chapter

Charter Member, 1984-1990, 1994-present

Councilor, 1985-1987

Vice President-Elect, 2005-2006

President, 2007-2008



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Professional Affiliations and Associated Appointments (Cont.)

British Toxicology Society (2006-present)
American Society for Pharmacology and Experimental Therapeutics, (1981-present)
 Drug Metabolism Division Member, 1981-1989
 Toxicology Section Member, 1989-1992
 Toxicology Division
 Charter Member, 1992-present
 Executive Committee, 1992
American College of Toxicology, Member, (1993-present)
American College of Occupational and Environmental Medicine, Associate Member, (1998-present)
American Academy of Veterinary and Comparative Toxicology, Fellow, (1985-present)
Society for Experimental Biology and Medicine, Member, (1978-present)
Teratology Society, Member, (1978-present)
 Constitution and Bylaws Committee Member, 1992-1994
 Committee on Expert Testimony, 1998-1999
Radiation Research Society, Member, (1981-present)

Review and Advisory Functions

External Advisory Board of the School of Public Health and Community Medicine, University of Washington (2005-present)
Reviewer, FY06 NIOSH National Occupation Research Agenda Program Project Review (2005)
Chairman, United States Environmental Protection Agency Arsenic Health Effects Research Peer-Review Panel, (1997)
National Research Council/National Academy of Science, Committee on Possible Effects of Electromagnetic Fields on Biologic Systems (1993-1996)
Scientific Advisory Committee, Vth COMTOX Symposium on Toxicology and Clinical Chemistry of Metals (1992-1995)
National Institutes of Health, Special Study Section on Possible Role of Metallothionein in Carcinogenesis (1993)
Risk Series Advisory Board, Waste-Management Education and Research Consortium Teleconference Series (1992)
Governor's Biotechnology Targeted Sector Advisory Committee, State of Washington (1989-1990)
Board of Directors, Washington State Biotechnology Association (1989-1990)
Advisory Council, Seattle Fire Department and the Washington State Fire Protection Services (1988-1990)
Reviewer, American Heart Association (1988-1990)
Reviewer, Department of Energy (1976-1990)
Reviewer, March of Dimes Birth Defects Foundation (1983-1990)
Industrial Advisory Board, Instructional Program in Toxicology, New Mexico State University (1982-1994)
Science Review Panel for Health Research, U.S. Environmental Protection Agency (1981-1989)
Reviewer, Air Force Office of Scientific Research (1985-1987)
Site review team at Harbor General Hospital for NICHHD (1978)
Reviewer, *International Journal of Toxicology*, *Journal of Occupational and Environmental Health*, *Teratology*, *Toxicology in Vitro*, *Toxicological Sciences*

Editorial Appointments

Program Leader, Environmental Risk Management Series, Waste-management Education and Research Consortium Teleconference Series (1992-1993)
Editorial Board, *Biological Effects of Heavy Metals*, CRC Press (1987-1993)
Co-Editor, *Interactions of Biological Systems with Static and ELF Electric and Magnetic Fields*, NTIS (1987)
Editorial Board, *Trophoblast Research*, Plenum Publishing Corporation (1983-1993)



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Other Professional Activities and Honors

Invited speaker, American Industrial Hygiene Conference & Exposition, June 2-7, 2007
Invited lecturer, Good Samaritan Hospital Grand Rounds, Phoenix, AZ, March 15, 2007
Invited speaker, Korea Environment of Merchandise Testing Institute, October 20, 2006
Invited speaker, Korea Food and Drug Administration, October 18, 2006
Invited speaker, Annual Meeting of the Risk and Insurance Management Society, April 23-27, 2006
Invited speaker, Annual Meeting of the Pacific Northwest Association of Toxicologists, September 8-9, 2005
Featured speaker, Annual Meeting of the St. Louis Chapter of the American Industrial Hygiene Association, March 11, 2005
Invited speaker, International Conference on Heavy Metal Toxicology, Taipei, Taiwan, October 15-16, 2004
Co-chair and speaker, roundtable, "Does funding influence research integrity?" 43rd Annual Meeting of the Society of Toxicology, 2004
Invited speaker, Puget Sound Occupational and Environmental Medicine Grand Rounds, University of Washington, October 9, 2003
Invited speaker, 1st International Symposium on National Toxicology Programs, Seoul, Korea, November 25, 2002
Invited speaker, Korean Occupational Health and Safety Administration, Seoul, Korea, November 26, 2002
Chairman, Safety Evaluation, 41st Annual Meeting of the Society of Toxicology, 2002
Chairman, Safety Evaluation, 40th Annual Meeting of the Society of Toxicology, 2001
Best IEQ-related paper published in 2000 in U.S. industrial hygiene journals. American Industrial Hygiene Association, 2001
Chairman, Risk Assessment, 38th Annual Meeting of the Society of Toxicology, 1999
Chairman, Risk Assessment, 37th Annual Meeting of the Society of Toxicology, 1998
Invited speaker, Congressional Commission on Risk Assessment and Risk Management, July 6, 1995
Invited speaker, Risk Assessment of Electromagnetic Fields, Electric Power Research Institute Annual Meeting, March 16, 1994
Chairman, Educator's Forum, 33rd Annual Meeting of the Society of Toxicology, 1994
Lead Presenter and Technical Producer, Environmental Risk Management Videoconference Series: Identifying the Gap Between Technical Issues and Social Concerns, April 14, 1993
Invited speaker, Health Risk Assessment for Environmental Chemicals, Annual Meeting of the American Chemical Society, March 1993
Invited lecturer, 3rd International Conference on Electrical and Electronic Materials, June 9, 1992
Invited lecturer, 8th International Congress on Thermal Insulation, March 9, 1992
Chairman, Risk Assessment II Session: 31st Annual Meeting of the Society of Toxicology, 1992
Invited panelist and lecturer, "Ask the Experts," Hazardous Waste Management Workshop, January 29, 1992
Invited panelist and lecturer, Risk Associated with Hazardous and Radioactive Wastes, Hazardous/Radioactive Waste Management Videoconference Training Series, WERC, April 24, 1991
Chairman, Cholinesterase Inhibitor Session: 30th Annual Meeting of the Society of Toxicology, 1991
Organizing Chairman, Molecular Biology Techniques Workshop, Annual Meeting of the Health Effects Institute, 1990
Chairman, Respiratory Physiology Session: 29th Annual Meeting of the Society of Toxicology, 1990
Chairman, Molecular/Cellular Session: 28th Annual Meeting of the Society of Toxicology, 1989
Co-Chairman, Toxicology/Metals Sessions: "11th Rochester Trophoblast Conference and the European Placenta Group," 1988
Co-Chairman, symposium: "Acute Radiation-Induced Injury," 26th Annual Meeting of the Society of Toxicology, 1987
Chairman, symposium: "Current Understanding of Metal-Membrane Interactions," 25th Annual Meeting of the Society of Toxicology, 1986
Co-Chairman, workshop: "Animal Placental Perfusions," 10th Trophoblast Conference, 1985
Co-Chairman, symposium: "Interactions of Biological Systems with Static and ELF Electric and Magnetic Fields," 23rd Annual Hanford Life Sciences Symposium, 1984
Chairman, Metals Session: 23rd Annual Meeting of the Society of Toxicology, 1984



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Other Professional Activities and Honors (Cont.)

Chairman and invited participant: Metabolism Session, "Developmental and Reproductive Toxicity of Metals," 15th Annual Rochester International Conference on Environmental Toxicity, 1982
Award of Merit, Northwest Chapter of the Society for Experimental Biology and Medicine, 1980
Invited participant, symposium: "Transport Processes as Sites of Action for Chemicals," Joint Fall Meeting of ASPET and SOT, 1978

Selected Continuing Education

REACH: A New Framework for the Regulation of Chemicals, March 25, 2007, Society of Toxicology Continuing Education Course (1 instructional hour)
Physiologically Based Pharmacokinetic Modeling for Risk Assessment Applications, March 25, 2007, Society of Toxicology Continuing Education Course (4 instructional hours)
Allergy and Allergic Disease: A Primer for Toxicologists, March 25, 2007, Society of Toxicology Continuing Education Course (4 instructional hours)
Comparative Endocrine Toxicology, March 5, 2006, Society of Toxicology Continuing Education Course (4 instructional hours)
Neuropathology for the Toxicologist, March 5, 2006, Society of Toxicology Continuing Education Course (4 instructional hours)
4th Annual Medical Toxicology Spring Course, March 2-3, 2006, American College of Medical Toxicology (16 instructional hours)
NIOSH Spirometry Training Course, October 13-14, 2005, Allenmoore Hospital (16 instructional hours)
Puget Sound Occupational & Environmental Medicine Grand Rounds: Welding, Manganese, and Parkinsonism, April 14, 2005 (1 instructional hour)
Development and Interpretation of Toxicokinetic Data for Risk and Safety Assessment, March 6, 2005, Society of Toxicology Continuing Education Course (4 instructional hours)
Basic Neurotoxicology, March 21, 2004, Society of Toxicology Continuing Education Course (4 instructional hours)
Skin Sensitization and Allergic Contact Dermatitis, March 21, 2004, Society of Toxicology Continuing Education Course (4 instructional hours)
The Importance of the Placenta in Developmental Toxicity and Human Health Risk Assessment, June 24, 2003, Teratology Continuing Education Course (4 instructional hours)
Evaluation of Immunomodulation in Safety Assessment, March 9, 2003, Society of Toxicology Continuing Education Course (4 instructional hours)
Cutaneous Toxicity – Current Methods and Concepts in Safety Evaluation and Relevance to Human Exposure, March 9, 2003, Society of Toxicology Continuing Education Course (4 instructional hours)
A Practical Approach to Blood and Lymphoid Tissue in Toxicology Assessments, March 17, 2002, Society of Toxicology Continuing Education Course (4 instructional hours)
Toxicology of Naturally-Occurring Toxins, March 17, 2002, Society of Toxicology Continuing Education Course (4 instructional hours)
Food Allergy and Intolerance, March 25, 2001, Society of Toxicology Continuing Education Course (4 instructional hours)
Mold and Mildew in Indoor Environments, November 12, 2000, American Public Health Association Continuing Education Institution Course (8 instructional hours)
Metal Exposure and Toxicity of the Respiratory Tract, March 19, 2000, Society of Toxicology Continuing Education Course (4 instructional hours)
Pulmonary Immunotoxicology, March 19, 2000, Society of Toxicology Continuing Education Course (4 instructional hours)
Gene Targeting/Null Models in Toxicology, March 14, 1999, Society of Toxicology Continuing Education Course (4 instructional hours)
Application of Transgenic Models in Toxicology, March 14, 1999, Society of Toxicology Continuing Education Course (4 instructional hours)
Effective Risk Communications: Avoiding the Pitfalls, March 1, 1998, Society of Toxicology Continuing Education Course (4 instructional hours)



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Selected Continuing Education (Cont.)

International Harmonization of Non-Clinical Toxicology Requirements: Regulation vs. Practice, March 1, 1998, Society of Toxicology Continuing Education Course (4 instructional hours)
The Role of Toxicology in Assessing the Safety and Risk of New Food Technologies and Practices, March 9, 1997, Society of Toxicology Continuing Education Course (4 instructional hours)
Epidemiology for Toxicologists, March 10, 1996, Society of Toxicology Continuing Education Course (4 instructional hours)
Quantitative Uncertainty Analysis in Risk Assessment: Monte Carlo Techniques, March 10, 1996, Society of Toxicology Continuing Education Course (4 instructional hours)
Comparative Endocrine Toxicology, March 5, 2006, Society of Toxicology Continuing Education Course (4 instructional hours)
Neuropathology for the Toxicologist, March 5, 2006, Society of Toxicology Continuing Education Course (4 instructional hours)

Publications

(1) = Research Paper; (2) = Review; (3) = Abstract

1. (3) Kelman, B.J. and A.R. Twardock. 1975. Calcium, sodium, and potassium movements across the perfused guinea pig placenta. *Fed. Proc.* 34: 558.
2. (3) Kelman, B.J. 1976. Movement of methyl mercury across the perfused guinea pig placenta. *Fed. Proc.* 35: 364.
3. (1) Kelman, B.J., G.E. Jarboe, and L.B. Sasser. 1976. Effect of red-cell-bound mercury on measurements of tissue mercury distribution. *Bull. Environ. Contam. Toxicol.* 16: 612-617.
4. (1) Kelman, B.J. 1977. Inorganic mercury movements across the perfused guinea pig placenta in late gestation. *Toxicol. Appl. Pharmacol.* 41: 659-665.
5. (3) Kelman, B.J. 1977. Movements of inorganic mercury across the perfused guinea pig placenta in late gestation. *Fed. Proc.* 36: 355.
6. (3) Kelman, B.J. 1977. Transport of cadmium across the guinea pig placenta in late gestation. In: University of Missouri 11th Annual Conference on Trace Substances in Environmental Health, Columbia, MO.
7. (1) Kelman, B.J., D.M. Bush, L.B. Sasser, and G.E. Jarboe. 1977. Respiration of mercury from rats and release of mercury from stored rat tissues treated with methylmercury chloride. *Health Phys.* 33: 139-141.
8. (1) Kelman, B.J. and L.B. Sasser. 1977. Methylmercury movements across the perfused guinea pig placenta in late gestation. *Toxicol. Appl. Pharmacol.* 39: 119-127.
9. (1) Kelman, B.J. and B.K. Walter. 1977. Passage of cadmium across the perfused guinea pig placenta. *Proc. Soc. Exp. Biol. Med.* 156: 68-71.
10. (3) Walter, B.K. and B.J. Kelman. 1977. Fetal uptake of methylmercury in swine. *Fed. Proc.* 36: 355.
11. (3) Kelman, B.J., J.A. Ozga, B.K. Walter, and L.B. Sasser. 1978. Cadmium-binding protein in the livers of pregnant and fetal rats. *Teratology* 17: 23A.
12. (3) Kelman, B.J. and A.R. Twardock. 1978. Calcium, sodium, and potassium movements across the placenta in the presence of inhibitors. *Fed. Proc.* 37: 615.



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Publications (Cont.)

13. (2) Kelman, B.J. and B.K. Walter. 1978. Use of perfusion in the study of placental transport of mercury and cadmium, pp. 555-567. In: *Developmental Toxicology of Energy-Related Pollutants*, D.D. Mahlum, M.R. Sikov, P.L. Hackett, and F.D. Andrew (eds.), 17th Hanford Life Sciences Symposium, October 17-19, 1977, Richland, WA. CONF-771017, NTIS, Springfield, VA.
14. (1) Kelman, B.J., B.K. Walter, G.E. Jarboe, and L.B. Sasser. 1978. Effect of dietary cadmium on calcium metabolism in the rat during late gestation. *Proc. Soc. Exp. Biol. Med.* 158: 614-617.
15. (1) Sasser, L.B., G.E. Jarboe, B. Walter, and B.J. Kelman. 1978. Absorption of mercury from ligated segments of the rat gastrointestinal tract. *Proc. Soc. Exp. Biol. Med.* 157: 57-60.
16. (3) Walter, B.K. and B.J. Kelman. 1978. Calcium-cadmium interactions in the rat during late gestation. *Fed. Proc.* 37: 614.
17. (3) Kelman, B.J. 1979. Cadmium movements between mother and fetus. In: *Regional Meeting of the Northwest Section for the Society for Experimental Biology and Medicine*, Richland, WA.
18. (2) Kelman, B.J. 1979. Effect of toxic agents on movements of materials across the placenta. *Fed. Proc.* 38: 2246-2250.
19. (1) Kelman, B.J., J.A. Ozga, B.K. Walter, and L.B. Sasser. 1979. Cadmium-binding in the pregnant and fetal rat. *Toxicol. Lett.* 4: 135-141.
20. (3) Kelman, B.J. and B.K. Walter. 1979. Fetal to maternal cadmium movements across the perfused hemochorial placenta of the guinea pig. *Toxicol. Appl. Pharmacol.* 48: A146.
21. (3) Sasser, L.B., P.T. Bronsky, B.K. Walter, and B.J. Kelman. 1979. The subcellular distribution and protein-binding of orally administered ^{109}Cd in the newborn rat intestine. In: *University of Missouri 13th Annual Conference on Trace Substances in Environmental Health*, Columbia, MO.
22. (1) Schneider, M.D., and B.J. Kelman. 1979. A proposed mechanism(s) of transitory ischemic injury to myocardium. *Am. J. Vet. Res.* 40: 170-182.
23. (3) Kelman, B.J., M.R. Sikov, and P.L. Hackett. 1980. Effects of monomeric ^{239}Pu on the pregnant and fetal rabbit. *Teratology* 21: 48A.
24. (1) Kelman, B.J., S.E. Steinmetz, B.K. Walter, and L.B. Sasser. 1980. Absorption of methylmercury by the fetal guinea pig during mid to late gestation. *Teratology* 21: 162-165.
25. (3) Kelman, B.J., S.E. Steinmetz, B.K. Walter, and L.B. Sasser. 1980. Distribution of tissue-bound methylmercury in the fetal guinea pig after maternal methylmercury administration, p. 20. In: *Abstracts of Papers, 19th Annual Meeting of the Society of Toxicology*, March 9-13, 1980, Washington, DC.
26. (1) Kelman, B.J. and B.K. Walter. 1980. Fetal to maternal cadmium movements across the perfused hemochorial placenta of the guinea pig. *Toxicol. Appl. Pharmacol.* 52: 400-406.
27. (1) Kelman, B.J. and B.K. Walter. 1980. Transplacental movements of inorganic lead from mother to fetus. *Proc. Soc. Exp. Biol. Med.* 163: 278-282.
28. (3) Sasser, L.B., A.A. Levine, B.J. Kelman, and R.K. Miller. 1980. The effect of fetal cadmium injection on metallothionein in fetal and maternal rat liver, p. 23. In: *Abstracts of Papers, 19th Annual Meeting of the Society of Toxicology*, March 9-13, 1980, Washington, DC.



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Publications (Cont.)

29. (1) Charles-Shannon, V.L., L.B. Sasser, D.K. Burbank, and B.J. Kelman. 1981. The influence of zinc on the ontogeny of hepatic metallothionein in the fetal rat. *Proc. Soc. Exp. Biol. Med.* 168: 56-61.
30. (3) Kelman, B.J. 1981. Alterations of the maternal blood supply to the fetus by toxic materials. *The Toxicologist* 2: 42.
31. (3) Kelman, B.J. and M.R. Sikov. 1981. Effects of intravenous injection of monomeric ^{239}Pu in pregnant rabbits, pp. 72-73. In: Abstracts of Papers, 29th Annual Meeting of the Radiation Research Society, May 31 - June 4, 1981, Minneapolis, MN.
32. (3) Kelman, B.J. and M.R. Sikov. 1981. Fetal exposure to plutonium. *The Toxicologist* 1: 146.
33. (3) Kelman, B.J. and M.R. Sikov. 1981. Movements of plutonium across the perfused guinea pig placenta. *Radiat. Res.* 87: 386.
34. (1) Kelman, B.J. and M.R. Sikov. 1981. Plutonium movements across the hemochorial placenta of the guinea pig. *Placenta (supplement)* 3: 319-326.
35. (3) Kelman, B.J. and D.L. Springer. 1981. Fetal exposure to benzo[a]pyrene. *Teratology* 23: 45A.
36. (1) Kelman, B.J. and D.L. Springer. 1981. Fetal exposure to benzo[a]pyrene across the hemochorial placenta, pp. 387-397. In: *Coal Conversion and the Environment: Chemical, Biomedical and Ecological Considerations*, D.D. Mahlum, R.H. Gray, and W.D. Felix (eds.), 20th Hanford Life Sciences Symposium, October 19-23, 1980, Richland, WA. CONF-801039, NTIS, Springfield, VA.
37. (3) Sasser, L.B., V.L. Charles-Shannon, B.D. Bergquist, and B.J. Kelman. 1981. The effect of zinc and cadmium on hepatic metallothionein in the fetal rat. *The Toxicologist* 1: 30.
38. (3) Sikov, M.R., B.J. Kelman, and P.L. Hackett. 1981. Effects of intravenous injection of monomeric ^{239}Pu in pregnant rabbits. *Radiat. Res.* 87: 446.
39. (3) Kelman, B.J. 1982. Teratological lesions and changes in the maternal blood supply to the fetus: A hypothesis. *Teratology* 25: 53A-54A.
40. (3) Kelman, B.J., D.D. Mahlum, and J.R. Decker. 1982. Effects of exposure to magnetic fields on the pregnant rat, p. 52. In: Abstracts, Fourth Annual Scientific Session of the Bioelectromagnetics Society, June 28 - July 2, 1982, Los Angeles, CA.
41. (3) Kelman, B.J. and M.R. Sikov. 1982. Clearance of a-aminoisobutyric acid during in situ perfusion of the guinea pig placenta, p. 12. In: *Proceedings of the Ninth Rochester Trophoblast Conference*, University of Rochester, Rochester, NY.
42. (3) Kelman, B.J. and M.R. Sikov. 1982. Toxicology of plutonium: Fetal distribution following maternal exposure. *Teratology* 26: 48A.
43. (1) Kelman, B.J., M.R. Sikov, and P.L. Hackett. 1982. Effects of monomeric ^{239}Pu on the fetal rabbit. *Health Phys.* 43: 80-82.
44. (1) Kelman, B.J., M.R. Sikov, and P.L. Hackett. 1982. Effects of monomeric ^{239}Pu on the pregnant rabbit. *Health Phys.* 42: 730-731.
45. (3) Kelman, B.J., M.R. Sikov, D.D. Mahlum, P.L. Hackett, D.L. Springer, and F.D. Andrew. 1982. An integrated approach to the evaluation of rat pups from dams exposed to high-boiling coal liquids. *Fed. Proc.* 41: 1560.



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Publications (Cont.)

46. (1) Kelman, B.J. and D.L. Springer. 1982. Movements of benzo[a]pyrene across the hemochorial placenta of the guinea pig. *Proc. Soc. Exp. Biol. Med.* 169: 58-62.
47. (1) Kelman, B.J., B.K. Walter, and L.B. Sasser. 1982. Fetal distribution of mercury following introduction of methylmercury into porcine maternal circulation. *J. Toxicol. Environ. Health* 10: 191-200.
48. (3) Sikov, M.R., B.J. Kelman, and D.D. Mahlum. 1982. Toxicology of plutonium: Intrauterine and postnatal effects of prenatal exposure. *Teratology* 26: 50A.
49. (2) Hackett, P.L. and B.J. Kelman. 1983. Availability of toxic trace metals to the conceptus. *Sci. Total Environ.* 28: 433-442.
50. (3) Hackett, P.L., M.R. Sikov, D.L. Springer, D.D. Mahlum, and B.J. Kelman. 1983. Teratologic studies of solvent refined coal process materials. *Toxicol. Lett.* 18: 77.
51. (1) Hackett, P.L., M.R. Sikov, D.L. Springer, D.D. Mahlum, and B.J. Kelman. 1983. Teratologic studies of solvent refined coal process materials, pp. 349-352. In: *Developments in the Science and Practice of Toxicology*, A.W. Hayes, R.C. Schnell, and T.S. Miya (eds.). Elsevier Science Publishers, Amsterdam.
52. (3) Kelman, B.J. and D.D. Mahlum. 1983. Life-time exposure of CD-1 mice to 1-T homogeneous and 2-T/meter gradient dc magnetic fields: A progress report after 8 months of exposure. In: *Abstracts, Fifth Annual Scientific Session of the Bioelectromagnetics Society*, June 12-17, 1983, Boulder, CO.
53. (3) Kelman, B.J. and M.R. Sikov. 1983. Absence of ultrasound effects on placental blood flow and function in the pregnant guinea pig. *Teratology* 28: 56A.
54. (1) Kelman, B.J. and M.R. Sikov. 1983. Clearance of a-aminoisobutyric acid during in situ perfusion of the guinea pig placenta. *Tropho. Res.* 1: 71-80.
55. (3) Kelman, B.J. and M.R. Sikov. 1983. Distribution of plutonium in the fetal rabbit following maternal exposure to monomeric ²³⁹Pu. *Fed. Proc.* 42: 627.
56. (3) Kelman, B.J., M.R. Sikov, R.A. Pappas, and H.D. Collins. 1983. Effect of ultrasound exposure on the function of the perfused guinea pig placenta. *J. Ultrasound Med.* 2: 42.
57. (3) Kelman, B.J. and D.L. Springer. 1983. Postnatal effects following prenatal exposure to solvent refined coal (SRC) materials. *Toxicol. Lett.* 18 (Suppl. 1): 142.
58. (3) Kelman, B.J., D.L. Springer, and R.B. Westerberg. 1983. Metabolic distribution of benzo[a]pyrene (BaP) in the circulation of the rodent. *The Toxicologist* 3: 566.
59. (3) Schirmer, R.E., R.B. Westerberg, L.J. Felice, B.J. Kelman, and D.L. Springer. 1983. Percutaneous absorption and metabolism of carcinogens associated with synfuel processing. *Toxicol. Lett.* 18 (Suppl. 1): 80.
60. (3) Sikov, M.R. and B.J. Kelman. 1983. Effect of ultrasound on maternal blood flow to the placenta and transplacental movements of a-aminoisobutyric acid (AIB). *Fed. Proc.* 42: 1129.
61. (3) Kelman, B.J., R.L. Rommereim, and D.D. Mahlum. 1984. Lifetime exposure of CD-1 mice to 1-T homogeneous and 2-T/meter gradient dc magnetic fields. In: *Abstracts, Sixth Annual Meeting of the Bioelectromagnetics Society*, July 15-19, 1984, Atlanta, GA.
62. (3) Kelman, B.J. and M.R. Sikov. 1984. Transplacental kinetics of metals from the actinide series. *The Toxicologist* 4: 167.



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Publications (Cont.)

63. (3) Kelman, B.J. and M.R. Sikov. 1984. Transplacental movements of americium-241 across the guinea pig placenta and early distribution kinetics within the dam. *Teratology* 29: 40A.
64. (3) Kelman, B.J., M.R. Sikov, J.A. Cushing, S.A. Watson, and R.A. Pappas. 1984. Effect of ultrasound on placental function. *Fed. Proc.* 43: 916.
65. (3) Kelman, B.J., R.L. Rommereim, and D.D. Mahlum. 1985. Toxicology of magnetic fields. *The Toxicologist* 5: 175.
66. (3) Kelman, B.J. and R.E. Weller. 1985. Electrocardiographic changes in the geriatric CD-1 mouse. *Fed. Proc.* 44: 464.
67. (1) Sasser, L.B., B.J. Kelman, A.A. Levine, and R.K. Miller. 1985. The influence of maternal cadmium exposure or fetal cadmium injection on hepatic metallothionein levels in the fetal rat. *Toxicol. Appl. Pharmacol.* 80: 299-307.
68. (1) Kelman, B.J., R.A. Pappas, and M.R. Sikov. 1986. Effects of ultrasound on placental function. *IEEE Trans. Ultrasonics, Ferroelectrics, and Frequency Control* . UFFC-33(2): 218-224.
69. (2) Anderson, L.E., B.J. Kelman, and R.J. Weigel (eds.). 1987. Interaction of Biological Systems with Static and ELF Electric and Magnetic Fields, 23rd Hanford Life Sciences Symposium, October 2-4, 1984, Richland, WA. CONF-841041, NTIS, Springfield, VA.
70. (2) Kelman, B.J. and B.K. van Kreel. 1987. Criteria for standardizing and judging viability of placental perfusions in animals. *Tropho. Res.* 2: 515-522.
71. (3) Sikov, M.R. and B.J. Kelman. 1987. Development of analytic models for placental transfer of the heaviest metals. *Proc. Soc. Exp. Biol. Med.* 186: 392.
72. (3) Kelman, B.J. and M.R. Sikov. 1988. Analytical components in modeling transplacental movements of the heaviest metals ($z \geq 82$). *The Toxicologist* 8: 191.
73. (2) Cockerham, L.G. and B.J. Kelman. 1988. Summary of symposium on acute radiation-induced injury. *Fundam. Appl. Toxicol.* 11: 571-579.
74. (3) Kelman, B.J. and M.R. Sikov. 1988. Evaluation of changes in placental function produced by ultrasound exposure. In: Abstracts, 11th Rochester Trophoblast Conference and the European Placenta Group, October 9-12, 1988, Rochester, NY.
75. (1) Sikov, M.R. and B.J. Kelman. 1989. Factors affecting the placental transfer of actinides. *Health Physics* 57: 109-114.
76. (3) Frazier, M.E., B.J. Kelman, L.L. Whiting, S.R. Peterson, and G.L. Stiegler. Oncogene activation in experimentally-induced lung tumors, p 63. In: Abstracts, 5th International Congress of Toxicology, July 17-21, 1989, Brighton, England.
77. (3) Kelman, B.J. and M.R. Sikov. 1990. Estimating fetal exposure to toxic materials. *The Toxicologist* 10: 123.
78. (3) Sikov, M.R., H.K. Meznarich, and B.J. Kelman. 1990. Radiation and chemical dosimetry of the embryo and fetus. *Teratology* 41: 592.



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Publications (Cont.)

79. (3) Kelman, B.J., J.U. Bell, and J.R. Millette. 1993. Resuspension of asbestos in settled dust: implications for risk assessment. *The Toxicologist* 13: 416.
80. (3) Kelman, B.J., J.U. Bell, and J.R. Millette. 1993. Resuspension of asbestos in settled dust. Abstracts of the Annual Meeting of the Health Effects Institute.
81. (3) Kelman, B.J. and J.U. Bell. 1993. Uncertainties in risk assessment of chemicals. Abstracts of the American Chemical Society.
82. (2) Kelman, B.J. 1993. Current Scientific Consensus Views of Health Effects from Low-level Electromagnetic Radiation. *Shepard's Expert and Scientific Evidence Quarterly* 1:243-253.
83. (1) Kelman, B.J., W.E. Wright, R.C. Lee, H.A. Haerer, R. Wilson, J. Negraeff, and G.R. Fox. 1994. A comparison of deterministic and stochastic models in a health risk assessment of a residential site containing arsenic (As)-contaminated soil. *The Toxicologist* 14:155.
84. (1) Kelman, B.J., J.R. Millette, and J.U. Bell. 1994. Resuspension of asbestos in settled dust in an apartment cleaning situation. *Applied Occupational and Environmental Hygiene* 9: 876-878.
85. (2) Kelman, B.J. and R.C. Lee. 1994. Toxicology, Uncertainty, and Health Risk Assessment; Waste-Management: From Risk to Remediation., R.I.S. Bhada, A. Ghassemi, T.J. Ward, M. Jamshidi, and M.Shahinpoor, eds., Vol. 1., pp. 73-84.
86. (3) Kelman, B.J., R.A. Perona, L.J. Swenson, and M.A.P. Kenrick. 1994. Human health risk associated with the impact of drilling mud on groundwater supplies. *The Toxicologist*, 15:141.
87. (3) Kelman, B.J., R.C. Lee, R. Zapf-Gilje, and L.J. Swenson. 1995. An international approach to the development of a risk assessment framework. *The International Toxicologist* 7.
88. (3) Kelman, B.J., L.J. Swenson, L.V. Uppala, P.R. Seidel, and W.F. Mueller. 1996. Health impact from chemical components of cellulose insulation. *Fundam. Appl. Toxicol.* 30: 107.
89. (3) Hueske, K.L., R.C. Lee, and B.J. Kelman. 1996. Background cancer risks from naturally-occurring arsenic. *Fundam. Appl. Toxicol.* 30: 49.
90. (3) Kelman, B.J., L.J. Swenson, L.V. Uppala, K.A. Kalbfleisch, and W.F. Mueller. 1998. A preliminary calculation of health risk associated with the use of insulation made from shredded paper. *Fundam. Appl. Toxicol.* 42: 40.
91. (1) Kelman, B.J., L.J. Swenson, L.V. Uppala, J.M. Cohen, J.R. Millette, and W.F. Mueller. 1999. Chemical components of shredded paper insulation: a preliminary study. *Applied Occupational and Environmental Hygiene* 14: 192-197.
92. (3) Lee, R.C., L. Swenson and B.J. Kelman. 1999. Uncertainty associated with carcinogenic potency of ethylene dibromide. *Toxicological Sciences* 48: 398.
93. (2) Robbins, C.A., L.J. Swenson; M.L. Nealley, R.E. Gots, B.J. Kelman, 2000. The health effects of mycotoxins in indoor air: A critical review. *Applied Occupational and Environmental Hygiene* 15: 773-784.
94. (3) Kelman, B.J., C.W. Jarand, and L.J. Swenson. 2001. Evaluation of potential health effects from exposure to isocyanates emitted during the use of paints and coatings. *Toxicological Sciences* 60: 322.



Bruce J. Kelman, Ph.D., D.A.B.T., F.A.T.S.

Publications (Cont.)

95. (3) Kelman, B.J., C.A. Robbins, and L. Swenson. 2002. Evaluation of potential health effects from inhalation exposure to mycotoxins in indoor office and residential environments. *Toxicological Sciences* 66: 267.
96. (1) Jarand, C.W., S.O. Akapo, L.J. Swenson, and B.J. Kelman. 2002. Diisocyanate emission from a paint product: a preliminary analysis. *Applied Occupational and Environmental Hygiene* 17: 491-494.
97. (1) Hardin, B.D., B.J. Kelman, and A. Saxon. 2002. Adverse Human Health Effects Associated with Molds in the Indoor Environment. Evidence-Based Statement, American College of Occupational and Environmental Medicine, <http://www.acoem.org/guidelines/article.asp?ID=52>.
98. (1) Hardin, B.D., B.J. Kelman, and A. Saxon. 2003. Adverse Human Health Effects Associated with Molds in the Indoor Environment. Evidence-Based Statement, American College of Occupational and Environmental Medicine, *J Occupation Environ Med.* 45:470-478.
99. (3) Jarand, C.W., C.A. Robbins, and B.J. Kelman. 2003. Evaluation of Potential Exposure to Volatile Organic Compounds Emitted from a Spray Grade Contact Cement, *Toxicological Sciences* 72:301.
100. (1) Kelman, B.J., C.A. Robbins, L.J. Swenson, B.D. Hardin. 2004. Risk from Inhaled Mycotoxins in Indoor Office and Residential Environments, *International Journal of Toxicology* 23:3-10.
101. (2) Van Loo, C. Robbins, L. Swenson, and B. Kelman. 2004. Growth of Fungi on Fiberglass Insulation Building Materials - A Review of the Literature. *Journal of Occupational and Environmental Hygiene* 1: 349-354.
102. (3) Kelman, B.J., B.D. Hardin, and R.L. Brent. 2005. Risk of Teratogenicity from Trichloroethylene (TCE) and Dichloroethylene (DCE) in Drinking Water, *Toxicological Sciences* 84: 429.
- 103.(2) Hardin, B.D., B.J. Kelman, and R.L. Brent. 2005. Trichloroethylene and Dichloroethylene – A Critical Review of Teratogenicity, *Birth Defects Research (Part A): Clinical and Molecular Teratology* 73:931-955.
- 104.(3) Chan, C.Y. and B.J. Kelman. 2006. Risk of Hepatotoxicity from Consumption of Usnic Acid, *Toxicological Sciences* 90:473.
- 105.(3) Hobden, J.E., R.H. Atallah, D. L. Sudakin, and B.J. Kelman. 2007. Risk and Symptomology from Inhalation Exposure to Solvent-Based Paint Vapor. *Toxicological Sciences* 96:311.



GLOBALTOX

SEATTLE • PORTLAND • GUELPH • HILTON HEAD • NEW YORK

Coreen A. Robbins, M.H.S., Ph.D., C.I.H.

Education

B.S., Zoology, Michigan State University, 1983.
M.H.S., Occupational Safety and Health, The Johns Hopkins University, 1989.
Ph.D., Environmental Health Science, The Johns Hopkins University, 1995.

Affiliations

American Industrial Hygiene Association
American Conference of Governmental Industrial Hygienists
Pacific Northwest Section of the American Industrial Hygiene Association

Certifications

Certified Industrial Hygienist #5605

Experience

2003 - Present	GlobalTox, Inc. <i>Principal – Senior Industrial Hygienist</i>	Redmond, Washington
1999-2003	GlobalTox, Inc. <i>Senior Industrial Hygienist</i>	Redmond, Washington
1998-1999	McConnell and Associates <i>Industrial Hygienist</i>	Bellevue, Washington
1994-1998	International Center for Toxicology and Medicine (formerly National Medical Advisory Service). <i>Senior Industrial Hygienist</i>	Bethesda, Maryland


PUBLICATIONS AND SELECTED PRESENTATIONS

Kelman, B.J., C.A. Robbins, L.J. Swenson, B.D. Hardin: Risk from Inhaled Mycotoxins in Indoor Office and Residential Environments. *International Journal of Toxicology* 23(1):3-10 (2004).

Van Loo, J., C. Robbins, L. Swenson, and B. Kelman, Growth of Fungi on Fiberglass Insulation Building Materials – A Review of the Literature. *Journal of Occupational and Environmental Hygiene*, 1:349-354 (2004).

C.A. Robbins, J. Morrell. Mold, Housing and Wood, *Western Wood Products Association* 2002.

P.N. Breyse, P.S.J. Lees, B.C. Rooney, B.R. McArthur, M.E. Miller, and C.A. Robbins: End-user exposures to synthetic vitreous fibers: II. Fabrication and installation fabrication of commercial products. *Applied Occupational and Environmental Hygiene* 16(4):464-470 (2001).





Coreen A. Robbins, M.H.S., Ph.D., C.I.H.

C.A. Robbins, L.J. Swenson, M.L. Nealley, R.E. Gots, B.J. Kelman: Health Effects of Mycotoxins in Indoor Air: A Critical Review. *Applied Occupational and Environmental Hygiene* 15(10):773-784 (2000). (Awarded "Best Indoor Environmental Quality Publication in 2000" by the American Industrial Hygiene Association Indoor Environmental Quality Committee, June 2001).

C.A. Robbins: Toxicology, Stachybotrys, and the Industrial Hygienist. American Industrial Hygiene Conference & Exposition. Roundtable 243, *Critical Review of Health Hazards from Exposure to Mycotoxic Fungi in Indoor Environments*, 25 May 2000.

C.A. Robbins, P.N. Breysse: The effect of vapor polarity and boiling point on breakthrough for binary mixtures on respirator carbon. *American Industrial Hygiene Association Journal* 57(8):717-723 (1996).

C.A. Robbins: *The Adsorption of Binary Organic Vapor Mixtures on Respirator Carbon*. Ph.D. Thesis The Johns Hopkins University (1995).

P.S.J. Lees, P.N. Breysse, B.R. McArthur, M.E. Miller, B.C. Rooney, C.A. Robbins, M. Corn: End user exposures to man-made vitreous fibers: I. Installation of residential insulation products. *Applied Occupational and Environmental Hygiene* 8(12):1022-1030 (1993).

C.A. Robbins, P.N. Breysse, M. Francis, P.S.J. Lees, N. Chopra, M. Corn: Comparison of size characteristics of fibers found on sample filters and cassette cowl from personal samples of airborne man-made mineral fibers. *Applied Occupational and Environmental Hygiene* 7(10):659-664 (1992).

B.J. Kelman, C.A. Robbins and L.J. Swenson. April 2002. *Evaluation of Potential Health Effects from Inhalation Exposure to Mycotoxins in Indoor Office and Residential Environments*. Toxicological Sciences 66:267.

L.J. Swenson, C.A. Robbins, W.T. Geer. June 2002, *Variability in Viable and Non-viable Mold Spore Sampling Results*, American Industrial Hygiene Association Conference, Poster session.

L.J. Swenson, C.A. Robbins, W.T. Geer. June 2001. *What's Growing in the Pacific Northwest?* AIHC, Poster session.

Invited Speaker: AIHA Pacific Northwest Section Annual Symposium: *Mycotoxins in Indoor Air: Exposure, Dose & IH Control Methods*. 4 April 2001, Lacey, WA.

Invited Speaker: University of Washington, Occupational & Environmental Medicine: New Developments for Primary Care Clinicians. *Mold Exposure in the Indoor Environment: Exposures and Health Effects*. 6 April 2001, Seattle, WA.

PROFESSIONAL COMMITTEES AND ACTIVITIES

AIHA Bioremediation Task Force

AIHA Toxicology Committee -